Comparison of Clinicopathological Parameters and Molecular Classification of Breast Cancers by Indumathi, K
  
COMPARISON OF CLINICOPATHOLOGICAL 
PARAMETERS AND MOLECULAR 
CLASSIFICATION OF BREAST CANCERS. 
 
Dissertation submitted in partial fulfilment 
of the requirements for the degree of 
 
 
M.D. (PATHOLOGY) 
BRANCH - III 
 
INSTITUTE OF PATHOLOGY, 
MADRAS MEDICAL COLLEGE, 
CHENNAI – 600 003. 
 
 
 
 
 
THE TAMIL NADU 
DR. M.G.R. MEDICAL UNIVERSITY 
CHENNAI 
APRIL 2015 
 CERTIFICATE 
 
This is to certify that this Dissertation entitled “COMPARISON OF 
CLINICOPATHOLOGICAL PARAMETERS AND 
MOLECULAR CLASSIFICATION OF BREAST 
CANCERS” is the bonafide original work of Dr.K.INDUMATHI, in 
partial fulfillment of the requirement for M.D., (Branch III) in Pathology 
examination of the Tamilnadu Dr.M.G.R Medical University to be held in 
April 2015. 
 
 
 
Prof. Dr. R.VIMALA, M.D.,     Prof. Dr.M.SARASWATHI, M.D., 
DEAN,                                                    DIRECTOR, 
Madras Medical College and                  Institute of pathology, 
Rajiv Gandhi Government General        Madras Medical College, 
Hospital,                            Chennai – 600003. 
Chennai – 600003                             
 


Submission author:
Assignment title:
Submission title:
File name:
File size:
Page count:
Word count:
Character count:
Submission date:
Submission ID:
Digital Receipt
This receipt acknowledges that Turnitin received your paper. Below you will find the receipt information
regarding your submission.
The first page of your submissions is displayed below.
201213003.md Pathology INDUMATH…
TNMGRMU EXAMINATIONS
COMPARISON OF CLINICOPATHO…
full_aligned.pdf
199.78K
117
19,778
99,659
22-Sep-2014 09:32PM
449014950
Copyright 2014 Turnitin. All rights reserved.
DECLARATION 
 
I Dr.K.INDUMATHI, solemnly declare that the dissertation titled 
“COMPARISON OF CLINICOPATHOLOGICAL PARAMETERS 
AND MOLECULAR CLASSIFICATION OF BREAST CANCERS” is 
the bonafide work done by me at Institute of Pathology, Madras Medical 
College under the expert guidance and supervision of Prof. Dr. M. 
SARASWATHI, M.D., Professor and Director of Institute of Pathology, 
Madras Medical College. The dissertation is submitted to the Tamilnadu 
Dr.M.G.R Medical University towards partial fulfillment of requirement for 
the award of M.D., Degree (Branch III) in Pathology. 
 
 
 
 
Place : Chennai 
Date :        Dr. K. INDUMATHI 
 
 
 
ACKNOWLEDGEMENT 
 
 
I express my sincere thanks to Prof. Dr. R. VIMALA, M.D., Dean, 
Madras Medical College and Rajiv Gandhi Government General Hospital, 
for permitting me to utilize the facilities of the Institution. 
 
I take this opportunity to express my heartfelt sincere gratitude to 
Prof. Dr. M. SARASWATHI, M.D., Professor and Director of Institute of 
Pathology, Madras Medical College, Chennai, for her constant 
encouragement, wholehearted support, valuable suggestions and expert 
guidance throughout the study, without which this study would not have 
ever been possible. 
 
I am thankful to Prof. Dr. P.KARKUZHALI, M.D., Professor and 
former Director of Institute of Pathology, Madras Medical College for her 
initial guidance and valuable suggestions during the study. 
 
        I am truly thankful to Prof. Dr. SHANTHA RAVISANKAR M.D. 
D.C.P, Prof. Dr. R. PADMAVATHI. M.D.,D.G.O., Prof. Dr. V. 
RAMAMURTHY M.D., Prof. Dr. GEETHADEVADAS M.D.,D.C.P., 
Prof. Dr. M.P. KANCHANA M.D., Prof. Dr. K. RAMA M.D., Prof. Dr. 
RAJAVELU INDIRA M.D., Prof. Dr. SUDHAVENKATESH M.D., and 
Prof. Dr. S. PAPPATHI M.D., D.C.H  and all my Assistant Professors, 
my colleagues, technicians and staffs of Institute of Pathology, Madras 
Medical College for their co-operation and encouragements during my study 
period. 
I sincerely express my heart felt gratitude to my most lovable parents 
Mr.M. Karnan and Mrs.Rani Karnan, my dear husband Dr. D. Thennarasu 
and my dear most sons Ezhilamudhan and Adavdeepan, for all their 
sacrifices, for creating adequate time for me to do my work and balanced 
my absence with love throughout the study period.   
Words are not enough to thank my sister Dr. K.sudha, my brother in 
law Dr. N.Adalarasan and statistician Mr. Padmanabhan for helping me in 
doing my statistics work. I would like to add a special mention about my 
friend Dr. M.Sai Sridevi for her constant support, valuable suggestions and 
encouragement.  
Above all I thank the ALL MIGHTY, for everything that he has given 
me. 
 
 
 
 
 
 
ABBREVIATIONS 
ER   : Estrogen receptor 
PR   : Progesterone receptor. 
RNA   : Ribonucleic acid 
DNA  : Deoxy ribonucleic acid 
HER 2  : Human epidermal growth factor receptor 2 
CK 5/6  : Cytokeratin 5/6 
ICMR  : Indian council of medical research 
EGFR  : Epidermal growth factor receptor.  
GCDFP   : Gross cystic disease fluid protein.  
DCIS  : Ductal carcinoma in situ. 
P53   : Protein 53 
RT PCR  : Reverse transcriptase polymerase chain    
                             Reaction 
FISH  : Fluorescent in situ hybridisation 
BRCA  : Breast cancer antigen 
LHRH  : Luteinizing hormone releasing hormone 
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ABSTRACT 
COMPARISON OF CLINICOPATHOLOGICAL PARAMETERS AND 
MOLECULAR CLASSIFICATION OF BREAST CANCERS. 
 
AIM:  
This is a retrospective study of 60 cases, to detect the expression of ER, PR, HER2neu, 
CK5/6 and Ki67 proliferation index in breast carcinomas by immunohistochemical method 
and to determine the newer molecular classification. Few patients have recurrence inspite of 
being diagnosed under the category of low risk and few do well in the high risk group which 
can be attributed to the molecular level differentiation. The aim of this study to classify the 
patients under molecular classification, to compare the clinicopathological parameters with it 
and to denote the significance of targeted therapy. 
MATERIALS AND METHODS:  
This is a retrospective study of detecting the expression of the above said markers in 
modified radical mastectomy specimens received at the Institute of Pathology, Madras 
Medical College and Rajiv Gandhi Government General Hospital, Chennai during the period 
from January 2011 to June 2013. 4 microns thick sections of the paraffin tissue blocks were 
Hematoxylin and eosin stained and reported as Infiltrating ductal carcinoma no special type 
(IDC NST) and its special variants like medullary, papillary, metaplastic, lobular, mucinous 
and apocrine carcinoma. A total of 60 cases which included 30 of IDC NST and 30 cases of 
special variants were selected for immunohistochemical analysis. 
RESULTS:  
Out of the 60 cases studied, the most common was found to be the luminal A type comprising 
37% and the least common was the luminal B and hybrid types each comprising 8%. The 
most common grade for HER2 was Grade III (50%). The association of histological grade 
with the molecular classification was statistically significant with the p value of 0.01. Basal 
type (56%) had the highest incidence of N3 stage.ER, PR, HER2 neu, CK5/6 expression and 
proliferation index with Ki67 had a statistically significant association with the molecular 
classification. High proliferation index (>14%) with Ki67 was noted in Luminal B, Basal and 
Hybrid types. 78% of the total 60 cases were alive and healthy. One death was reported in 
HER2, Hybrid and Basal types. The negative kappa value obtained while studying the 
agreement between the histopathological and molecular classification, indicates that the 
agreement is worse than chance and hence the importance of molecular classification is 
substantiated for the targeted therapy. 
CONCLUSION:  
                   To conclude, breast cancers are heterogenous and having diverse clinical 
outcomes, these researches on molecular subgroups would pave way towards the 
“personalisation” of treatment for breast cancers with the more feasible and economic tool of 
immunohistochemistry. 
KEY WORDS: Molecular Classification, Histopathological Classification, 
immunohistochemistry with ER, PR, HER2 neu, CK 5/6 and Ki67, Targeted Therapy. 
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INTRODUCTION 
 
Of all the female cancers, breast carcinoma comprises 16% of the 
total cases and is one of the most commonly diagnosed cancers worldwide. 
[1]
 Although it is the most common cause for cancer related deaths in 
developing countries overtaking the cervical cancers with relatively poor 
survival. Its incidence in India is 30-33% per 1,00,000 women and the 
relative risk is 0.033(1 in 30).
 [2] 
Early diagnosis and treatment will certainly 
reduce the mortality rates. 
            Breast cancers are categorised into two types based on their cell of 
origin as (i) Ductal carcinoma and (ii) Lobular carcinoma. Lobular 
carcinoma comprises 10-20% of breast cancer cases and ductal carcinoma 
80-90%.
 [3, 4] 
Breast cancers vary widely in behaviour with regard to thelikelihood 
of local and distant metastasis, recurrence and response to therapy. Study of 
tumour molecular characteristics has enhanced our understanding of both 
the tumor behaviour and the response to therapy.
 [3]
 
These molecular markers in breast cancer have gained importance not 
only as prognostic indicators but also as predictors to therapeutic 
response.Especially the steroid receptors -estrogen receptor (ER), 
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progesterone receptor (PR), HER2 neu, CK5/6 and Ki67 have gained 
increasing interest. 
[5] 
Recent advances in breast pathology that examines the RNA, DNA 
and proteins of malignant cells have provided an algorithm for the new 
molecular classification of breast cancers.
 [5, 6]
 Based on the gene expression 
profiling, five major patterns of gene expression has been identified: 
Luminal A, Luminal B, HER2 type, Basal and unclassified types. 
[5, 6]
 
This classification correlates wellwith the prognosis and response to 
treatment. The most favourable long term disease free survival is seen with 
Luminal A type tumors. However the tumors most sensitive to 
chemotherapy are the basal type and HER2 subtypes but the overall 
prognosis of these tumors worst. 
[7, 8]
 
In this study of 60 cases which included invasive ductal carcinoma no 
special type(IDC NOS) and its special variants, an attempt has been made to 
evaluate the hormonal status and proliferation index by 
immunohistochemistry. Further the histological grade and other prognostic 
factors were correlated. 
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AIMS AND OBJECTIVES 
 
 
1. To identify the relative frequency and distribution of breastcarcinoma 
in the population. 
2. To study the histomorphological features of breast 
carcinomaincluding grade, lymph node status, lymphovascular 
invasion,lymphocytic response and necrosis. 
3. To assess the expression of ER, PR, HER 2 neu, CK5/6 and Ki67 in 
invasive breast carcinomas. 
4. To subtype the breast cancers based on their expression of these   
markers as Luminal type A, Luminal type B, HER2 neu type and 
Basal type. 
5. To compare the clinicopathological parameters and molecular 
classification of breast carcinoma. 
6. To assess the correlation between histopathological classification and 
molecular classification. 
7. To denote the significance of molecular classification in the treatment 
of the patients. 
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REVIEW OF LITERATURE 
Invasive breast carcinomas aremalignant duct epithelial tumours 
which exhibit invasion of the adjacent tissues, with an increased tendency 
for distant metastasis.
 [9] 
Breast carcinoma is one of the cancers commonly 
described in ancient documents due to its visibility. 
[10]
 
The oldest description of breast cancers was given in 1600 BC, by 
Edwin Smith Papyrus.
 [10, 11]
The first documented case of breast cancer was 
described by Imhotep in 2650 BC.
 [12]
 
Leonides (30 AD) compared cancers to crabs, due to the tenacious 
adherence to the surrounding tissues. 
 [13]
 In 1874, Paget described the 
changes in the nipple that preceded breast cancer and it continues to bear his 
name.
 [14]
 
Radical mastectomy was first performed by William Stewart 
Halstedin 1882. 
[15]
 X-rays were discovered by Wilhelm Conrad Röntgen 
in1895 and it forms the basis for mammogram and radiotherapy.
 [16, 17]
  
In 1925, Greenhough was the first to evaluate grading system for 
breast cancer.
[18]
 In 1928, Scarff et al proposed tubule formation, nuclear 
pleomorphism and hyperchromasia as criteria to grade breast cancers. 
[19]
 In 
1957, Bloom and Richardson proposed the numeric scoring system based on 
tubule formation, nuclear pleomorphism and mitosis for gradingadapted by 
WHO.
[20,21]
In 1983, Bloodgood et al recognized ductal carcinoma in situ 
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where neoplastic cells are limited within the terminal duct lobular unit.
[22,23]
 
Early 1990, Nottingham modification of Bloom Richardson grading system 
was adapted by WHO.
[24, 25] 
 
EPIDEMIOLOGY 
According to the 2001-03 ICMR report, breast cancer constitutes 
about 25% of the total cancers among Indian women.
 [26, 27, 28]
Breast cancers 
are the second most common in Indian rural women after cervical cancers 
and it is the most common cancer in metropolitan cities.
 [29]
 
In India, the crude incidence rate of breast carcinoma is 85/1,00,000 
women/year.
 [30]
 The death per incident ratio is highest in India, with 50% 
compared to 30% in China and 18% in the United States.
 [31]
 
The annual age-adjusted rate is 30 to 33 per 1,00,000 in urban  
women and 8.6 per 1,00,000 in rural women.
 [32] 
India is rapidly stepping towards industrialization resulting in lifestyle 
changes. This probably contributes to the increase in breast cancer incidence 
in our country. 
The presenting symptoms include breast lump, nipple discharge, 
retraction or eczema. Screening for breast abnormalities are done by the 
triple assessment which includes clinical examination, imaging and tissue 
sampling. 
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RISK FACTORS: 
 Many risk factors are implicated in the development of breast 
cancers.Some studies have proposed that the common denominator for most 
of these factors is strong and prolonged estrogen stimulation that takes place 
on a genetically susceptible background. 
[33]  
The strongly associated risk 
factors are family history of first degree relative
[34]
 with breast carcinoma, 
early menarche, nulliparity, late age at first child birth, 
[35]
 late menopause, 
sedentary life style with high calorie diet, obesity, long term exposure to 
hormone replacement therapy with estrogen alone, 
[36,37]
 oral contraceptive 
pills
[38]
 and  ionising radiation. 
[39, 40]
 
 
ETIOLOGY: 
 The two main etiological factors involved in breast carcinoma are 
hormone excess and genetic predisposition. 
 
Estrogen and breast cancer 
The main function of estrogen is stimulation of cell growth and 
proliferation by acting via estrogen receptor (ER) as a transcriptional 
activator. 
[41]
 However, this process is slow. Recently, a non genomic 
pathway has been demonstrated which does not involve ER, but acts 
through a G-protein coupled receptor, GPR30. These result in activation of 
metalloproteinases and cleavage of heparin - bound epidermal growth 
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factor. The released EGF then acts on its receptor, EGFR and stimulates cell 
proliferation.
[42]
 The existence of this pathway indicates that drugs acting 
only through ER may not be enough to inhibit tumour growth. 
 
Genes involved in Breast Cancer 
Hereditary breast cancers are about 5% to 10%. BRCA1 and BRCA2 
are the major genes involved in hereditarybreast cancer. The BRCA1 gene 
is present on chromosome 17q and itsproduct is responsible for DNA repair. 
The increased risk of occurrences of breast cancer, ovarian cancer and 
pancreatic cancer are associated with these mutations. 
[43, 44]
Patients with 
BRCA2 gene mutations present on chromosome 13q have increased risk of 
male breast cancers, prostatic cancers,pancreatic cancers and cutaneous 
melanomas.
[45, 46] 
Invasive ductal carcinoma is a group of breast carcinoma 
in which the stromal invasion of malignant cells is evident beyond the 
epithelial component. Current histomorphological subtyping of breast 
carcinoma is based on World Health Organisation classification (Annexure 
II). 
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BREAST CANCER CLASSIFICATION. 
Histopathological classification: 
The breast is composed of groups of lobules and divided into 12 to 25 
lobes. Acini are grape like clusters of glands which comprise the lobule and 
secrete the breast milk. Milk is delivered to nipple by thin tubular structures 
connecting the lobules. (Fig.1). Fatty and connective tissue occupies the 
remaining space. Ductal carcinoma arises from the ductal epithelial cells 
and lobular carcinoma from the lobes and lobules. 
 
 
 
Fig 1: Anatomy of female breast. 
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Rarely, breast cancers can occurin fat, muscles and blood vessels 
which form the connective tissue stroma. Those cancers are called sarcoma 
and they comprise less than 1% of breast cancer and less than 5% of all soft 
tissue sarcomas. 
[47]
 Breast cancers are also classified based on the 
invasiveness as (i)invasive (infiltrating) cancers and (ii) non-invasive (in 
situ) carcinomas.  Breast cancers with generalised inflammation of the 
breast are called the inflammatory breast cancer which is another rare type. 
The frequency and 10 year survival of various histological types of invasive 
ductal carcinomas.(Table 1). 
Table 1: The frequency and 10 year survival of 
histopathologicalsubtypes of invasive ductal carcinoma. 
S.NO 
HISTOPATHOLOGICAL 
TYPE OF INVASIVE BREAST 
CANCER 
FREQUENCY (%) 10 YEAR 
SURVIVAL (%) 
1 IDC NOS 50-60 35-50 
2 Inflammatory carcinoma 1-6 30-40 
3 Apocrine carcinoma 1-4 LIKE IDC NOS 
4 Medullary carcinoma 5-7 50-90 
5 Metaplastic carcinoma <5 Unknown  
6 Mucinous carcinoma <3 85-95 
7 Papillary carcinoma 1-2 Unknown  
8 Tubular carcinoma 1-2 90-100 
9 Invasive lobular carcinoma 5-15 35-50 
10 Adenoid cystic carcinoma 0.1 85-100 
11 Neuroendocrine carcinoma 2-5 Unknown  
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INVASIVE DUCTAL CARCINOMA NOSPECIAL TYPE (IDC NST) 
IDC NST accounts for 75-80% of breast cancers and is the most 
common type. 
[48]
 These tumors lack sufficient characteristics to be 
classified as a specific histological type as tubular or mucinous carcinoma.  
These tumours elicit a marked fibroblastic stromal reaction and produce a 
firm palpable mass. It may produce dimpling of the skin due to traction on 
the suspensory ligaments.  
Grossly, the tumour is ill defined, firm, with a yellow grey cut 
surface, with infiltrating borders as radiating trabeculae into the surrounding 
parenchyma, resulting in a stellate appearance. Histologically, the tumour 
cells are arranged in a variety of patterns such as acinar configurations, 
cords and broad sheets of cells, with surrounding dense stroma. The tumours 
show a wide range of differentiation with poorly differentiated tumours 
showing solid sheets of pleomorphic cells. These tumours are graded using 
Nottingham modification of Scarff Bloom Richardson system (Annexure 
III). 
MEDULLARY CARCINOMA 
It is common in patients under 50 years of age, particularly associated 
with BRCA1 mutations carriers.
 [49] 
Grossly, the tumour is well 
circumscribed and becomes larger and resembles fibroadenoma clinically 
and grossly. Its cut surface is homogeneous, solid and grey with occasional 
foci of necrosis. Rarely do they present as cystic masses. Microscopicallythe 
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tumor borders are always of pushing margins. They show a diffuse pattern 
of growth with minimal or no glandular differentiation or intraductal growth 
component and absence of mucin production. The cells are arranged in solid 
sheets of large pleomorphic cells with prominent nucleoli, forming a 
syncytium. The tumour has scant fibrous stroma and frequent mitotic 
figures. Numerous lymphocytes surround the sheets of tumour cells with 
most of them being cytotoxic T lymphocytes.
[50]
  They typically express 
CK7, often express vimentin , S-100 and P53, but not CK20.
[51]
 They are 
almost invariably negative for hormone receptors as well as HER2 neu 
(„triple negative‟ phenotype).Axillary nodal metastasis are common and 
overall prognosis is better than the invasive ductal carcinoma especially for 
tumors less than 3 cm in size despite the nodal metastasis. 
MUCINOUS CARCINOMA 
It commonly occurs in postmenopausal women. It is also known as 
colloid, mucoidor gelatinous carcinoma. Grossly, it is well circumscribed 
with a glistening jelly like mass held together by delicate septa. 
Microscopically, the tumour cells form small clusters and appear to float in 
a sea of mucin. These clusters may be solid, exhibit acinar formations or 
form micropapillary structures.
[52]
Mucin is almost always extracellular and 
it may be of acid or neutral type.
[53]
Histochemically, the mucins secreted by 
this tumour are distinct O-acylated forms of sialomucins.
[54]
  
Immunohistochemically, there is strong MUC2 cytoplasmic 
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immunoreactivity and decreased MUC1 immunoreactivity compared with 
ductal carcinoma NOS.
[55] 
 Hormone receptors are always positive, while 
HER2 neu is almost always negative.
[56]
Nearly half of the cases of mucinous 
carcinoma show neuroendocrine differentiation light microscopy showing 
nests of cells with salt and pepper chromatin expressing neuroendocrine 
markers as neuron specific enolase, chromogranin and synaptophysin and 
presence of dense core granules by ultrastructural examination. Pure 
mucinous carcinomas are those in which the mucin occupies more than 90% 
of the tumor component and mixed mucinous carcinomas show 50% of 
mucin with 50% of tumor cells. 
APOCRINE CARCINOMA 
These tumors comprise 1- 4% of the breast cancers and is an 
uncommon type. More than 90% of the tumour is composed of apocrine 
cells.
[57]
There are two types of apocrine cells – Type A cells have abundant 
acidophilic granular cytoplasm which contains  golden brown granules 
which are strongly Periodic acid schiff positive  and Type B cells have 
clear, foamy cytoplasm. The nuclei are vesicular and nucleoli are prominent. 
Glandular differentiation is often found and associated with the 
characteristic bulbous expansion in the luminal side (Apocrine snouts). 
Ultra structurally the cells of apocrine carcinoma are rich in mitochondria 
and membrane bound vesicles with dense homogenous osmophilic cores. It 
is negative for bcl2, PR and ER. It expresses GCDFP 15. 
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METAPLASTIC CARCINOMA 
This is an uncommon variant of ductal carcinoma, in which the 
predominant component of the tumor has an appearance other than 
epithelial and glandular type and more in keeping with another cell type.
 [58]
 
It is a rare neoplasm.
 [59]
 Tumors that have overt carcinomas with 
direct transition to osseous or cartilaginous matrix are referred to as “matrix 
producing carcinomas”. [60, 61] The neoplasm is heterogeneous showing areas 
of spindle, squamous,  osteoclast type of giant cells, choriocarcinomatous 
elements, melanoma like or mesenchymal differentiation ranging from 
osseous and chondroid differentiation to frank sarcoma. Grossly, they 
present as well delineated, firm, pearly white sometimes bluish and 
glistening mass representing cartilaginous areas. Overall, they are more 
aggressive than IDC NOS. 
TUBULAR CARCINOMA 
It commonly occurs in patients around 50 years of age. Grossly, it is 
characteristically small, measuring about 1cm with poorly circumscribed 
margins and hard consistency. Microscopically, it is characterised by the 
haphazard arrangement of well differentiated, irregular and angulated glands 
in a desmoplastic stroma with the lining cells being small and regular. 
Periphery often shows invasion of fat. Necrosis, mitosis and pleomorphism 
are characteristically absent. Low-grade DCIS and flat epithelial atypia are 
thought to be precursor lesions of tubular carcinoma.
[62, 63] 
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CRIBRIFORM CARCINOMA 
These tumours accounts for 0.8 to 3.5% of breast carcinomas. 
Histologically, more than 90% of tumour shows cells arranged resulting in a 
cribriform- sieve like pattern similar to that seen in the in situ counterpart 
but with stromal invasion. This pattern is often seen in association with 
tubule formation, the relative proportion of the two elements determines the 
terminology used.
 [64]
 
 
INVASIVE PAPILLARY CARCINOMA 
These tumours accounts for less than 1 to 2 % of breast carcinoma. 
Frequently occurs in post-menopausal women. Most papillary carcinomas of 
breast are predominantly or entirely in situ lesions. Fischer et al first 
reported that invasive papillary carcinoma is grossly circumscribed. 
Microscopically, the invasive papillary carcinomas may be of papillary type 
or ordinary ductal type.The cells are arranged as delicate or blunt papillae 
with amphophilic cytoplasm. Many a times the intra cystic papillary 
carcinomas are invasive ones with the cystic component and pushing 
margins. Absence of myoepithelial cells helps in arriving at the diagnosis. 
Prognosis is better than IDC NOS. 
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INVASIVE MICROPAPILLARY CARCINOMA 
They account for less than 2% of the breast cancers and are highly 
invasive tumours. They are characterised by formation of papillary and 
pseudo papillary structures lacking a fibro vascular core.  They show a high 
nuclear grade and half of the cases show psammoma bodies. 
[65]
 
NEUROENDOCRINE CARCINOMA 
 They constitute about 5% of all breast carcinomas. It comprises 
carcinoid tumours, large cell neuroendocrine carcinomas and small cell 
carcinomas. The term “carcinoid” was proposed for those invasive tumors 
that exhibit neuroendocrine differentiation. 
[66]
Multicentricity and 
bilaterality can occur.
[66]
Microscopically, the neoplastic cells are small, 
arranged in solid nests separated by fibrous stroma. Ribbons and rosette like 
formations may be seen. Mitoses are generally rare. They express 
neuroendocrine markers in more than 50% of the tumour cell and this 
feature helps to distinguish them from breast carcinoma with focal 
endocrine differentiation.
[67] 
INVASIVE LOBULAR CARCINOMA
 
Lobular carcinoma is the second commonest type of breast cancer 
accounting for 10% of the cases. The tumour is more often bilateral and 
multicentric. The amount of stromal reaction varies from scanty to dense 
desmoplasia and therefore it may present as a discrete mass or diffuse 
indurated area.  The stroma often shows periductal and 
16 
 
perivenouselastosis.The tumour cells are small, uniform and bland looking 
often arranged in Indian file pattern or may form concentric arrays around 
ducts resulting in targetoid pattern. 10% of cases show mixed features of 
invasive ductal and lobular carcinomas. It is characterised by the presence 
of High molecular weight keratin, lack of accumulation of p53, and most 
importantly, decrease or absence of E-Cadherin. 
[68, 69, 70]
 
INFLAMMATORY CARCINOMA 
 In this type of breast cancer, the entire breast is reddened, warm with 
widespread oedema of the skin. Pathologically, it revealed an 
undifferentiated carcinoma with widespread lymphatic permeation. Presence 
of dermal lymphatic invasion that is confirmed by a skin biopsy, even 
though clinically not apparent, is an ominous sign. Such cases are called 
occult inflammatory carcinoma.
[72] 
 
MOLECULAR CLASSIFICATION 
Breast cancer is a pathologically and clinically heterogeneous disease.  
It has been a tradition that the details regarding the status of the patient 
which includes the tumor size, histological grade, histological type and 
nodal status were provided to the oncologists by the pathologists. Later on 
along with this the hormonal status were also evaluated and the breast 
tumors were broadly categorised as low risk (ER positive,nodes negative, 
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tumor size<1 cm and low grade) and high risk (ER negative, nodes positive, 
tumor size>1 cm and high grade) tumors. 
Approximately 15% of the patients end up with recurrence or die due 
to metastasis even among the low risk category, despite the best treatment 
and paradoxically 15% of the patients of high risk category have a 
favourable prognosis. So eventually approximately 15% of patients are put 
under mistreatment because of this system of classification of high and low 
risk group. 
Morphologically, similar tumours may show difference in prognosis 
and response to treatment. It is proposed that these molecular differences 
between the tumors of similar histology exhibits different clinical 
behaviour. Modern techniques like Immunohistochemistry (IHC), DNA 
microarray technology, Quantitative RT-PCR and FISH are ideally suitable 
to reveal the molecular differences between the same or different groups of 
histopathological specimens. 
[1]
 
IHC was discovered 30 years before and it is used as tool to classify 
tumors of breast into ER positive and negative tumors. FISH which was 
developed 20 years ago is used for the classification of breast tumors into 
HER2 amplified or HER2 non-amplified categories.
 [2, 3] 
Breast tumor cells generally overexpress hormone receptors as well 
as human epidermal growth factor-2 (HER2 neu) receptor for breast 
carcinoma formation and its progression. Therefore, based on the hormone 
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receptor expression, three groups of breast carcinomas were identified  as (i) 
ER/PR positive (ii) ER/PR negative andHER2 positive and (iii) triple 
negative (ER, PR and HER2 negative). 
The classification of breast carcinoma on the basis of hormone 
receptor status improves the  clinical outcome and prognosis of ER positive 
tumours as ER positive cancer cells depends on estrogen for its growth  and 
the treatment of  those patients with anti-estrogenic agents (e.g. Tamoxifen) 
will inhibit its proliferation and control its progression. Generally, HER-2 
positive tumors had a worse prognosis, in spite of HER-2 positivetumors 
showing a good response to the monoclonal antibody Transtuzumab. When 
conventional chemotherapy is combined with transtuzumabthe clinical 
outcome and pathological complete response to therapy has improved 
significantly. 
 [2]
 
Sorlie et al and Perou et al in the earlier parts of the decade 
demonstrated the “heat maps” generated by the microarray technique in 
which the “clustering analysis” technique was used to find the patterns of 
expression of 426 genes.
 [7]. 
The study of expression of these genes, lead to 
the subclassification of breast tumors which are similar to those of 
histologically and immunohistochemically classified tumor. For example 
luminal A category corresponds to the low risk group and luminal B with 
those to the HER 2 positive group. By demonstrating the positivity for ckit, 
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p63, EGFR, and CK 5/6, basal like tumors are distinguished from other 
subtypes. 
[76]
.  
Immunohistochemistry has become surrogate simplified advancement 
for DNA microarray gene expression classification. This tool has become a 
reliable method to identify the major molecular subtypes. This technique is 
an easy, reproducible and an economically feasible alternative for the 
analysis of prognostic factors.
 [72] 
 Based on the gene expression profiling  the latest molecular 
classification segregates breast cancer into four types (i) luminal, (ii) basal, 
(iii) HER2 and (iv) normal /unclassified type
[7, 74, 75]
 (Fig. 2). Breast cancer 
patients are broadly classified into two main categories based on the ER 
status as analysed by the hierarchical cluster analysis generated by using 
gene profile data. ER positive tumours (luminal type) are further classified 
into Luminal A which does not express HER2 and has a low proliferation 
index whereas Luminal B express HER2 along with ER and low molecular 
weight keratins. ER negative tumours are further classified into HER2 type 
which shows strong positivity for HER2 whereas Basal type which are 
negative for all three markers. High proliferation is noted in Luminal B, 
HER2 and Basal types.
 [74, 75] 
Luminal A tumors are those which are ER strong positive, PR 
variable positive, and negative for HER2, EGFR and CK5/6. It is the most 
frequent subtype and itshows a good prognosis and responds well to 
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hormonetherapy. Several studies have reported that ER+ tumors show little 
response to conventional chemotherapy.  
Identification of luminal B tumors is a point of controversy when they 
are identified at the protein level. Some authors have found that the HER 2 
associated genes are expressed in 35-50% of luminal tumors. However, 
tumors under this subtype have a worse prognosis than Luminal A tumors. 
This tumor requires deprivation of estrogen in combination of transtuzumab 
that blocks HER2. 
 The HER2+ subtypes are tumors which express only HER2 neu, and 
these tumors often has high proliferation index. When tumors express strong 
copositivity of hormone receptors and HER2 neu they are categorised into 
the separate hybrid type called the “luminal–HER2 hybrids.” [72] 
Cheang et al. stated that the hallmark of luminal B tumors was a Ki67 
proliferation index of more than 13.25%. Ki67 is demonstrated in the 
proliferating cell population, and its expression with nuclear positivity is 
directly proportional to the aggressive nature of the tumor.
 [72] 
HER2+ tumors are those which are ER and PR negative, HER2 
positive, and CK5/6 negative with high proliferation index. Overexpression 
of HER2 implies a poor prognosis. It demonstrates the highest sensitivity to 
neoadjuvantchemotherapy based on taxanes and anthracyclins.The poor 
prognosis of HER2 is due to its high riskof early relapse.
[72]
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Basal‑ like tumors aretriple negative with CK5/6 and/orEGFR 
positive, and with high proliferation index.The basal type is so named 
because of its pattern of expression that is similar to basal epithelial and 
myoepithelial cells of breast tissue.Using IHC, this class has also been 
called “triple negative”for not expressing ER, PR, or HER2. It has been 
associated with the BRCA1mutation
 [8, 4]
. Ribeiro et al. demonstrated that 
normal luminal cells express CK5/6 and these cells originate as the basal 
phenotype of breast cancer and undergo malignant transformation. Low 
regulation of BRCA1leads to an abnormal proliferationof these cells by 
stimulation of the p53 expression.
 [76]
 These tumors are very aggressive, 
with high grade, and p53 mutation.
 [76]
Several studies have demonstrated the 
poor outcome of this class. And it is still not clear if this poor outcome is 
due to a lack of therapeutic options or due to an inherent aggressiveness of 
the tumor. For being triple negative, they do not benefit the conventional 
targeted therapy.  However, they respond with high sensitivity to 
chemotherapy.With regard to the targetedtherapeutic options, some trials 
suggest that basal class tumors can be managed with the monoclonal 
antibodies against the epidermal growth factor.
 [72, 76] 
Unclassified (pentanegative) tumors are hormone receptors 
negative,HER2 negative, and CK5/6 and EGFR negative. Those triple 
negative tumors which lack the expression of the basal markers correspond 
to the unclassified tumors. Normal like tumors were earlier considered 
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synonyms to this subtype but currently the “normal‑ like” subtype is 
different from the unclassified (penta −ve) “ER−, PR−, HER2−, and CK5/6 
and EGFR−” group, as the concept of reduced expression of biomarkers is 
not a consistent finding of normal like cancers. 
[72] 
The unclassified type has 
a good prognosis and 6% of pathologic complete remission rate.
 [72, 74, 76] 
 
Fig.2. Dendrogram of molecular classification of breast cancers based 
on immunohistochemistry: 
 
 
 
  
 
Molecular subclasses show great difference in clinical outcome as per 
relapse free survival (RFS) and overall survival (OS) is concerned as shown 
Unclassified  
(penta negative) 
Luminal B 
(Weak ER+,PR+ and 
variable HER2 2) 
Luminal A 
(ER+, PR+, HER 2 
neg)  
Basal -ER-, PR-
HER2 -,CK5/6 + 
high Ki67 
HER2- ER-PR-, 
HER2 ++,  
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in Table 2. Among the subtypes, basal and HER2 are associated with worse 
outcome and shortest survival time
 [1]
. 
Table 2: Molecular subtypes and its outcomes. 
 
MOLECULAR 
TYPE OF 
BREAST 
CANCER 
FREQUENCY 
(%) 
5 
YEAR 
OS (%) 
5 
YEAR 
RFS 
(%) 
10 
YEAR 
OS (%) 
10 
YEAR 
RFS 
(%) 
LUMINAL A 50-60 85-95 80-90 75-85 75-85 
LUMNAL B 5-10 70-80 65-75 55-65 54-64 
BASAL 10-20 63-73 60-70 57-67 45-55 
HER 2 10-20 55-65 15-20 45-55 15-30 
NORMAL-
LIKE 
10-15 84-94 80-90 75-85 72-82 
 
RFS: This is the percentage of patients who are symptom free during the period between 
the day of breast surgery and the date of second episode of breast carcinoma. 
 OS: This is the percentage of patients who survived during the period between the day 
of breast surgery and date of death related or unrelated to breast cancer. 
 
 
 
PROGNOSTIC FACTORS 
Patient's age:  
Women younger than 50 years of age have the best prognosis. Relative 
survival declines after 50 years. 
Size:  
The tumour size shows a good correlation with the nodal status and survival 
rate.
[78, 79] 
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Cytoarchitectural type:  
There is no significant prognostic difference between ordinary invasive 
ductal and invasive lobular carcinoma.
[80]
 Morphologic variants of invasive 
ductal carcinoma with a more favourable prognosis are tubular carcinoma, 
mucinous carcinoma, medullary carcinoma, cribriform carcinoma, adenoid 
cystic carcinoma, papillary carcinoma, and secretory carcinoma.Metaplastic 
carcinoma,Squamous cell carcinoma, invasive carcinoma with 
neuroendocrine features and signet ring cell carcinoma behave in an 
aggressive way.
 [81]
 
Microscopic grade:  
Tumours are graded based on Nottingham modification of the Scarff 
Bloom–Richardson system (Annexure III). Ellis et al reported this grading 
system to have excellent correlation with patients‟ survival and rate of 
metastasis. 
[24] 
 
Axillary node metastases:  
Metastasis to axillary nodes has a significant impact on prognosis. There is a 
marked difference in survival between patients with positive and negative 
nodes and the survival rate also varies depending on the level of axillary 
node involved, their absolute number, the amount of tumour cells in the 
node, 
[82]
 the  presence or absence of tumor cells in the efferent blood 
vessels and presence or absence of extranodal spread. 
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 Other factors reported to have poor prognosis include tumour necrosis, 
lymphocytic infiltration and skin infiltration, association with pregnancy, 
lactation,
[83] 
BRCA mutation, 
[84] 
vimentin and keratin expression. 
[85]
 
IMMUNOHISTOCHEMISTRY (IHC) 
IHC is a molecular technique which was first described by Dr.Albert 
Coons in 1941. The original method consisted of an antibody developed in 
rabbits and then tagged with a fluorescent probe. It was mixed with tissue 
sections and examined using a fluorescent microscope after a period of 
incubation. Since then, numerous advancements have been made. 
[86]
The 
most commonly used techniques are the peroxidase -antiperoxidase immune 
complex method developed by Sternberger in 1970 and the biotin-
avidinimmunoenzymatic technique developed by Heitzman and Richards in 
1974. 
[87, 88] 
USES OF IMMUNOHISTOCHEMISTRY IN 
BREASTPATHOLOGY
[89, 90]
 
1. The use of myoepithelial markers to assess stromal invasion. 
2. E Catherin to differentiate between ductal and lobular carcinoma. 
3. High molecular weight cytokeratins to distinguish between ductal 
carcinoma in situ and usual ductal hyperplasia  
4. Cytokeratin stains to detect sentinel lymph nodes metastasis. 
5. To find the site of origin in metastatic cancers. 
6. Assessment of Estrogen and Progesterone receptor status &HER2neu 
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overexpression using specific antibodies to receptor proteins. 
7. Evaluation of spindle cell lesions to distinguish metaplastic 
carcinomafrom mesenchymal lesions. 
8. Assessment of proliferation index along with hormone receptor status and 
basal markers expression, and to classify as molecular subtypes. 
ANTIGEN RETRIEVAL 
Shi et al in 1991developed the antigen retrieval technique, in which 
he used a heating method at high temperatures to bring out the antigenicity 
of the tissue which had been masked by formalin fixation.  
 Antigen retrieval can be done by proteolytic induced epitope retrieval 
or heat induced epitope retrieval 
HEAT INDUCED EPITOPE RETRIEVAL 
In this technique, tissue sections are placed in the retrieval solution 
which is heated for varying period of time that leads to the breakdown of 
protein cross-links which are formed during fixation with formalin and 
recovers the tissue antigenicity.
 [91]
 
Commonly used heating devices are the pressure cooker, microwave 
oven, autoclave, steamer and water bath. Heating is usually done for about 
20 minutes followed by 20 minutes of cooling. The retrieval solution 
commonly used is the Citrate buffer with pH 6.0.  
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PROTEOLYTIC INDUCED EPITOPE RETRIEVAL 
[92]
 
Proteases liketrypsin, proteinase K, chymotrypsin and pepsin are used 
for restoring the tissue antigenicity. However, the limitation of this 
technique is thatsome epitopes are destroyed during this process and 
therefore alter the tissue morphology. 
TARGET ANTIGEN DETECTION METHODS 
After addition of specific antibodies to the antigens, next step is to 
visualize the antigen antibody reaction complex. The methods employed are 
the direct and the indirect methods. The direct method is a one-step staining 
procedure in which a labelled antibody directly reacts with the antigen in the 
tissue sections. Most commonly used labels are fluorochrome, horse radish 
peroxidase and alkaline phosphatase. Although this method is simple, rapid, 
and uses only one antibody, the sensitivity is lower. This is because signal 
amplification is less, and therefore it is not as commonly used when 
compared to the indirect methods.  
In the indirect method, first layer is formed by an unlabelled primary 
antibody which binds to the target antigen. Then, a second layer is formed 
by using a labelled secondary antibody that reacts with the primary 
antibody. This technique is more sensitive than the direct method because of 
better signal amplification. This is due to the binding of several secondary 
antibodies with conjugated fluorochrome to each primary antibody. 
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Anotheradvantage with this method is that it uses only a small number of 
secondary antibodies.
 [93] 
HORMONE RECEPTORS 
 A significant milestone in the management of breast cancer is the 
realisation of the presence of hormone receptors in the tumors, which 
correlated well with the response to hormonal therapy and chemotherapy. 
[94, 95]
 Currently the estrogen receptor status is regarded as the most powerful 
predictive factor in the management of breast cancer. Though ER and PR 
are co dependant variables, PR is a weaker predictor of response to hormone 
therapy than ER. 
[96]
 
 Hormone receptors are measured by the immunohistochemical 
method and attempts are made to semi quantitate them by standardizing the 
technical procedure and reporting by using appropriate controls.
 [97, 98, 99,100] 
Delay in fixation alters the results significantly. 
[101]
The two parameters are 
evaluated by counting the number of tumour nuclei stained and given in 
percentage of the entire tumour cell nuclei and the intensity of the staining 
reaction. 
[102]
 
Generally ER negative tumours tend to have grade three histology, 
lymphoid stroma, pushing margins, comedo type of necrosis and central 
fibrosis.
 [103]
 Most medullary, metaplastic and apocrine carcinomas are 
negative whereas tubular, mucinous, lobular carcinomas show a high degree 
of positivity.
 [104,105,106]
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For ER and PR, only nuclear reactivity is considered significant. 
When present in more than 5% of tumor cells they are regarded as positive 
and when in less than 5% of tumor cells they are regarded as negative.  
[107]
 
The guideline recommendations for immunohistochemistry testing of 
ER and PR receptors in breast cancer was jointly formulated by the 
American Society of Clinical Oncology and the College of American 
Pathologists (ASCO/CAP)
[108,109]
 Some of the more salient points of this 
document are the following: 
   
•     The pathologist must report the percentage of cells that are 
immunoreactive 
   
•     Tumours having 1% or higher invasive cancer cells staining are 
regarded as positive. 
   
•     The average intensity of the stain must be included (weak, moderate or 
strong). 
   
•     The pathologist must give an interpretation as to whether the sample is 
positive or negative. 
   
•     The use of a composite score based on percentage plus intensity 
(Allred, H, or Quick scores) is optional. 
   
•     Specimens should be placed in 10% neutral buffered formalin no later 
than 1 hour (but ideally much sooner) after being removed from the 
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patient. 
   •     Fixation time should be at least 6 hours and not longer than 72 hours. 
   
•     Normal breast cells in the sample can be used as internal positive 
controls. 
HER 2 neu 
It is a member of EGFR (epidermal growth factor receptor) family and 
is an oncogene that encodes a transmembrane glycoprotein.
 [110,111]
The 
development and progression of certain aggressive breast cancer is associated 
with the amplification and overexpression of this oncogene. It can be 
measured by immunohistochemistry or FISH.
[112,113,114] 
Theyare graded by 
immunohistochemistry according to the scheme in Annexure IV. Its 
overexpression is found in high grade DCIS, 20-30% of invasive ductal 
carcinomas and rarely in invasive lobular carcinoma.
 
Cytokeratin 5/6 
 CK 5/6 is a type II keratin which belongs to the high molecular 
weight category. Myoepithelial cells of the breast, glandular epithelium and 
the basal cells of the prostate some ovarian tumors show strong expression 
of this marker.
[115]
 They are considered to be a very good indicator of 
squamous and transitional epithelium and a good discriminator of 
mesothelioma and adenocarcinoma of lung.
[116] 
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 CK 5/6 expression in breast carcinoma indicates a basal like 
molecular subtype and is associated with adverse prognosis. It is also used 
in differentiating benign from malignant breast lesions as staining reaction 
in malignant lesions are only cytoplasmic and the intensity is less compared 
to the benign ones.
[117] 
 CK 5/6 scoring was done based on the criteria proposed by 
Smedts
[118] 
and Ordonez 
[119]
 in their studies on gynaecological 
malignancies. The scoring was done by counting the positive cells and they 
are given in a percentage (Annexure V). 
 Cytokeratin 5/6 staining has a wide variety of staining patterns from 
identifying the myoepithelial cell layer which shows a strong cytosolic 
staining, whereas identifying a layer of ductal epithelial cells shows a 
variable positivity and that may represent committed stem cells. 
Ki67 
 The rate of proliferation within the tumor cells can be detected with 
this molecule. The Ki67 labelling index (LI) has been used as an indication 
for evaluation and many reports have shown its clinical significance in a 
variety of tumors irrespective of their origin. 
Proliferation activity of breast carcinomas has been studied by 
various methodologies.  Investigators use either immunohistochemistry for 
studying the proliferating cell nuclear antigen (PCNA) expression or flow 
cytometry to measure the fraction of S-phase.
 [120,121].
In breast cancers a high 
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proliferation index correlates with a worse prognosis. Later gene expression 
profiling studies largely included the proliferation genes PCNA and Ki67 
and revealed the “molecular portraits” [122] 
Collosoet al have found the superior prognostic and predictive value 
of Ki67 than the other proliferation markers as cyclin 
D,cyclinE,p21,p27,topoisomerase II alpha.
[123] 
Among breast cancers it has 
been found that the average Ki67 labelling index was highest for high grade 
tumors and low for HER 2 positive tumors. 
For Ki67 nuclear reactivity is taken into account,which is recorded as 
continuous variables,based on the proportion of positive tumor cells (0%-
100%) irrespective of the staining intensity.They are regarded as high when 
>14% and low when <14%. 
 
STAGE WISE TREATMENT OF INFILTRATING DUCTAL CARCINOMA. 
 According to stage, for early breast cancer, the appropriate 
management would be breast conservative surgery. Mastectomy is done for 
large tumors. To shrink the bulky tumors before surgery, preoperative 
neoadjuvant chemotherapy is given. For tumors larger than 1 cm adjuvant 
systemic chemotherapy is advisable following surgery. Radiation therapy 
will be required for patients who had a breast conserving surgery, or some 
who have a modified radical mastectomy with margins involved, with 
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lymphovascular invasion and more than 4 nodes showing secondary 
carcinomatous deposits. 
STAGE I 
 These tumors are relatively smaller in size less than 2 cm and either 
have no nodal involvement or have sentinel lymph node involvement. 
Local therapy: 
Lumpectomy or Modified radical mastectomy(MRM) is the mainstay 
of treatment for stage I tumors. Radiation therapy is given after breast 
conservative surgery and treated without radiation if the patient is more than 
70 years old, tumor size less than 2 cm and when the tumor is completely 
removed with no nodal involvement. Hormonal therapy may be given for 
those who show hormone receptors positivity. 
[5, 6]
. 
Adjuvant systemic therapy: 
 No matter how small the tumor is, all cases that express hormone 
receptors are treated with hormonal therapy. For HER 2 positive tumors, 
Herceptin is usually recommended. 
 
STAGE II 
 These are tumors of large size that are spread to less than 4 lymph 
nodes. 
Local therapy: 
 Surgery followed by radiation therapy.  
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Adjuvant systemic therapy: 
 For all tumors in this stage, adjuvant systemic chemotherapy is 
recommended. Depending on the age, hormone receptor status, HER 2 
status hormonal therapy or Herceptin or chemotherapy or a combination of 
these is given. 
Neoadjuvant therapy: 
 It is an option for patients who opt for a breast conservative surgery 
wherein they are subjected to systemic therapy pre operatively to shrink the 
tumor size. If the tumor size does not shrink to the expected size, the 
adjuvant chemotherapy would likely to be of different set of drugs. For HER 
2 positive tumors Herceptin is also used as neoadjuvant therapy. 
 
STAGE III 
Stage III tumors are those which are of large size of more than 5 cm 
size or several nodal involvement or spreading into adjacent structures (skin 
over the breast or muscle underneath). Neoadjuvant systemic therapy 
followed by modified radical mastectomy with adjuvant therapy (hormonal 
therapy if hormone receptors positive, Herceptin if HER2 positive) and 
radiation therapy following surgery are recommended. 
ADJUVANT DRUG THERAPY 
Based on the prognostic factors like tumor size and lymph nodes 
involved, adjuvant therapy is considered valuable in the treatment of stage I 
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to III breast tumors. It can be chemo therapy, hormonal therapy, Herceptin 
or a combination of these. 
HORMONAL THERAPY 
Regardless of tumor size and lymph node involvement, it is the 
treatment for hormone receptor positive cancers. It is not likely to respond 
for hormone receptor negative tumor patients. Tamoxifen and LHRH analog 
drugs are used in hormone receptor positive tumors in women who have not 
attained menopause. Aromatase inhibitors are given to women who have 
become postmenoupausal within five years of tamoxifen treatment. 
Chemotherapy:  
For all hormone receptor negative and positive tumors, chemotherapy 
gives added benefit based on the stage and characteristics of their tumor by 
reducing the rate of recurrence. 
Drug combinations most commonly used are: 
 TAC: Taxotere, adriamycin, and cyclophosphamide 
 FAC: 5 Flurouracil, adriamysin and cyclophosphamide. 
 Herceptinis added to all for HER2/neu positive tumors along with the 
conventional chemotherapy. 
 
STAGE IV  
Bones, liver, lung and brain and lymph nodes are involved in this 
stage. Although surgery and radiation can help to some extent, the main stay 
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of treatment is systemic therapy. Combination of chemotherapy or targeted 
therapy or hormone therapy may be given. This will help to shrink the 
tumor size and improve the patients symptomatically. However all these 
therapies have possible side effects that should also be encountered while 
treating these patients. 
 Radiation therapy is given to treat small number of metastasis 
confined to one area, to relieve compression in spinal metastasis, to provide 
relief of pain and other symptoms and to treat brain metastasis
 [12]
. 
RECURRENT BREAST CANCER 
  Recurrent cancers are those that come back after treatment either in 
the local or in the distant area. Regional recurrences are breast cancers that 
recur in lymph node. Involvement of opposite breast is considered as new 
cancer. 
 The recurred tumor is surgically removed, subjected to radiation 
therapy or given targeted chemo therapy. Regional recurrence and distal 
recurrence are also treated similarly with the change in the chemo therapy 
either by adding newer drugs to old regimen or substituting the previously 
given drugs.  
 
TARGETED THERAPY FOR BREAST CANCER 
 These are recent drugs that specifically target the cells that cause 
cancer which are identified on the basis of gene expression profiling. 
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HORMONAL THERAPY 
 Tumors those are positive for ER and PR are treated with tamoxifen 
and aromatase inhibitors depending upon their postmenopausal status. 
 
HER2 TARGETED DRUGS. 
 These includespertuzumab (Perjta), Transtuzumab (Herceptin), 
lapatinib (Tykerb), and ado tarnstuzumabemtansine. 
ANTI ANGIOGENESIS DRUGS 
 For cancer cells to grow, they need adequate blood supply. This is 
achieved by neo angiogenesis as the VEGF and PDGF are stimulated by the 
cancer cells that leads to the proliferation of newer vessels. They show 
increased vascular invasion that ultimately affect the prognosis adversely. 
OTHER TARGETED THERAPIES 
 Everolimus and exemestane are other newer drugs that help hormone 
therapy to work better. These drugs play a better role in shrinking the breast 
tumor size when given in combination with hormonal therapy drugs than 
when given alone. Bisphosphonates, denozumab and vitamin D are other 
drugs that reduce fractures and strengthen the bones. 
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ROLE OF MOLECULAR CLASSIFICATION IN THE TREATMENT 
OF BREAST CANCERS. 
  The gene expression signatures of the various genes expressed in 
breast cancer are used in this classification. Morphologically identical breast 
carcinomas can have varied responses to therapy. This is because,there exist 
molecular level difference between morphologically similar tumors
 [126]
. 
Initial studies in molecular classification claimed that these signatures 
would provide an objective assessment of the risk of relapse and would be 
more reproducible than the currently used methods. As a result, the 
predictive factors for the different treatments, point that molecular 
classification is a more powerful tool.The on-going and upcoming 
researches may provide us with more precise prognostic and predictive 
information about breast cancer and perhaps serves as a breakthrough step 
towards “personalization” of breast cancer treatment. [124] New biological 
insights and targeted therapy towards the particular molecular subtypes are a 
result of better knowledge and understanding of the molecular 
classification.
[125]
.This would result in the less frequent use of chemotherapy 
by choosing the appropriate drugs that would target the cancer cells and 
thereby it can provide a considerable advantage in reducing the drug related 
toxicities and costs.
 [126]
 
  Molecular classification can also be used in the assessment of 
prognostic and predictive values. Gene expression differences are found to 
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exist between the cancers that recurred and those that did not recur. On 
evaluating these differentially expressed genes, scoring is obtained to 
predict the outcome.
[125] 
 
MOLECULAR CLASSIFICATION BY 
IMMUNOHISTOCHEMISTRY 
 
Immunohistochemical analysis (IHC) can also be used to classify 
tumors based on molecular classification with a limited panel of markers 
(ER, PR, HER2 neu, Ki67 and CK5/6). Apart from having distinct clinical 
outcomes, these subgroups have distinct clinical and morphological 
features. Subsequent studies have proposed a standardised molecular 
classification based on IHC to facilitate its clinical application and promote 
more uniform large multicentric studies.
[127]
. 
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MATERIALS AND METHODS 
This study is a retrospective descriptive study ofinvasive breast 
cancers conducted in the Institute of Pathology, Madras Medical College 
and Rajiv Gandhi Government General Hospital, Chennai during the period 
between Jan 2011 to Jun 2013. 
Source of data 
The invasive ductal carcinoma cases reported in mastectomy specimen 
received in the Institute of Pathology, Madras Medical College between Jan 
2011 to Jun 2013from the Department of General Surgery, Surgical 
Oncology and Plastic surgery, Rajiv Gandhi Government General Hospital. 
A total of 369 mastectomy specimens (simple, modified radical or radical 
mastectomy) were received during this period. 
Inclusion criteria: 
 All modified radical mastectomy specimens of breast carcinomas. 
 All invasive breast carcinomas no special type (ductal and lobular), 
medullary, mucinous, papillary, apocrine and metaplastic carcinomas 
irrespective of the age and sex were included for the study. 
Exclusion criteria: 
 All trucut biopsies. 
 Phylloides tumors. 
 Benign breast lesions. 
 Tumors with preexisting premalignant conditions. 
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 Recurrent tumors. 
METHOD OF DATA COLLECTION 
Detailed history of the cases regarding age, sex, menstrual 
history,side of the breast, type of procedure, history of neo adjuvant 
therapy,details of gross characteristics such as tumour size, nodal status 
detailswere obtained for those 60 cases included in the study that was 
reported during the study period from surgical pathology, surgical 
oncology and medical oncology records. Formalin fixed tissue were cut, 
processed and paraffin embedded.  
4 μm thick sections of the paraffin tissue blocks were cut and stained 
with eosin and hematoxylin. Slides were collected from slide filing and 
were reviewed and graded using the Nottingham modificationof the 
Scarff Bloom Richardson Grading system (Annexure III) and theywere 
further evaluated for the presence of necrosis, lymphocytic responseand 
lymphovascular invasion, skin infiltration by tumour. 10 cases of each 
grade fromInvasive ductal carcinoma NSTand 5 cases from special type 
as medullary, metaplastic, mucinous, apocrine, papillary and invasive 
lobular were randomly selected from thetotal cases and their 
representative formalin fixed paraffin embeddedtissue samples were 
subjected to immunohistochemical analysis of 5 markers which includes 
ER, PR, H2N, CK5/6 and Ki67. Slides were evaluated and scoring was 
given. The results were recorded with photographs. 
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IMMUNOHISTOCHEMICAL EVALUATION 
Immunohistochemical analysis of ER, PR, H2N, CK5/6 and Ki67 was 
done in paraffin embedded tissue samples using supersensitive polymer 
HRP system based on non-biotin polymeric technology. 
Table 3: Immunohistochemical markers used in the current study 
Antigen Vendor Clone Dilution Positive control 
ER Dako Rabbit 
Monoclonal 
EP1 
Ready to 
use 
Breast  
PR Dako Mouse 
Monoclonal 
Ready to 
use 
Breast  
H2n Dako Rabbit 
Monoclonal 
SP-3 
Ready to 
use 
Breast  
CK5/6 Dako Mouse 
Monoclonal 
Ready to 
use 
Squamous cell 
carcinoma of  skin 
Ki67 Dako Mouse 
Monoclonal 
Ready to 
use 
High grade 
lymphoma 
 
4 μ thick sections from selected formalin fixed paraffin embedded 
tissue samples were transferred onto gelatin coated slides. Heat induced 
antigen retrieval was done using microwave method. The ER, PR, CK5/6 
and Ki67 antigens are bound with mouse monoclonal antibodies (dako) and 
HER2neu antigen is bound with rabbit monoclonal antibody(dako). 
Laterantigen antibody complex are detected by the addition of secondary 
antibody conjugated with horse radish peroxidase-polymer and 
Diaminobenzidine substrate. The step by step procedure of 
Immunohistochemistry is given in Annexure IV. 
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INTERPRETATION & SCORING SYSTEM 
ER and PR 
Hormone receptors like estrogen and progesterone receptor, when 
expressed show a nuclear positivity. The number of cells expressing and 
their intensity of staining is scored as two values and a composite score 
based on percentage plus intensity of more than 2 is considered to be 
positive.(Annexure V).  
H2N: 
HER2neu expression is demonstrated in tumor cells as cytoplasmic 
membrane positivity and its intensity and number of tumor cells expressing 
is graded as 1+, 2+ and 3+. (Annexure V) 
CK 5/6 
CK 5/6 scoring was done based on the criteria proposed by Smedts et 
al
[118] 
and Ordonez et al
[119]
 in their studies on gynaecological malignancies. 
The scoring was based on the percentage of positive cells (Annexure V). 
Ki67 
For Ki67 nuclear reactivity is taken into account,which is recorded as 
continuous variables,based on the proportion of positive tumor cells (0%-
100%) irrespective of the staining intensity.They are regarded as high when 
>14% and low when <14%. 
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Molecular subtypes were derived and compared with the 
clinicopathological parameters with the SPSS version 17 software.  
McNemar test  
Description: 
 The Mcnemar‟s test is done by a 2x2 classification table. This is done 
to test the difference between paired proportions. Here in this study it is 
done on the same set of patients who serve as their own control, based on 
the “before and after” design. Two discrete dichotomous variables are used 
in the classification system. 
 In the current study 60 cases were classified on the basis of 
histopathology and the same set of patients were subjected to 
immunohistochemistry and classified under molecular classification. The 
difference between the two classification systems and 95% confidence 
interval were determined. The p value was derived and its significance was 
studied. 
INTER RATER AGREEMENT KAPPA 
DESCRIPTION: 
Inter rater agreement is used to evaluate the strength of agreement between 
two classification systems. The agreement is quantified by the KAPPA 
statistic. 
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 KAPPA is 1; when the agreement between the two classification 
systems is perfect. 
 KAPPA is 0; when there is no agreement better than chance. 
 KAPPA is negative; when agreement is worse than chance.  
The Standard errors reported by MedCalc are the appropriate standard 
errors for testing the hypothesis that the underlying value of weighted kappa 
is equal to a prespecified value other than zero. 
Table 4: Kappa value and its related strength of agreement 
K value Strength of agreement 
<0.2 Poor 
0.21-0.4 Fair  
0.41-0.6 Moderate  
0.61-0.8 Good 
0.81-1.0 Very good 
 
The value of KAPPA, with its standard error and 95% confidence 
interval was derived. The agreement between the two classification systems 
was analysed. 
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OBSERVATION AND RESULTS 
 
In the study period of 29 months from January 2011 to June 2013, a 
total of 26,536 specimens were received in the Institute of Pathology, 
Madras Medical College for histological examination. 
Total numbers of breast specimens received were 1412 cases, ofthese 
breast tumours accounted for 1023 cases with a percentage of 3.85% of all 
cases (including both incisional and excisional biopsies).  
The total number of non neoplastic, benign and malignant cases was 
289, 472 and 651 respectively. Thus the distribution of non neoplastic breast 
lesions were 20.46%, benign tumours were 33.42% and of malignant 
tumours were 46.11% is shown below in Table 5 and chart 1 
Table 5: Distribution of breast cases. 
 Non neoplastic Benign  Malignant  
Breast  289 472 651 
 
Out of a total of 651 breast cancer cases, 369 cases constituted radical 
mastectomy specimens. Among these 369 cases a total of 60 cases were 
included in this study which comprised of 30 cases of Infiltrating ductal 
carcinoma NST and 30 cases of special variants which included apocrine, 
medullary, mucinous, metaplastic, lobular and papillary carcinomas each 
constituting 5 cases.(Table 6, Chart 2). 
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Table 6: Distribution of cases included in the study 
HISTOPATHOLOGICAL 
CLASSIFICATION 
No of cases (%) 
Infiltrating ductal carcinoma no 
special type (IDC NST) 
30 (50) 
Metaplastic carcinoma 10 (8.3) 
Papillary carcinoma 10 (8.3) 
Lobular carcinoma 10 (8.3) 
Apocrine carcinoma 10 (8.3) 
Medullary carcinoma 10 (8.3) 
Mucinous carcinoma 10 (8.3) 
 
 ER, PR, HER2, CK5/6 and Ki67 were done for all 60 cases, results 
interpreted and scoring was given. Based on which they were classified into 
luminal A, luminal B, HER 2, basal and unclassified as per molecular 
classification.  
 
Among the 60 cases, 22 cases were luminal A and  constituted the 
most common type (36.7%), followed by 14 cases of basal type(23.3%),  8 
cases of HER2 (13.3%), 6 cases of unclassified (10%) and 5 cases of 
luminal B and hybrid types(8.3%). As seen in Table 7 and Chart 4. 
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Chart 1: Distribution of total breast cases. 
 
 
 
Chart 2: Distribution of cases included in the study 
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Table 7: Distribution of Molecular Subtypes in the current study 
Molecular 
subtypes 
Luminal A Luminal B HER 2 Hybrid Basal Unclassified  
No of cases 
(%) 
22(36.7) 5(8.3) 8(13.3) 5(8.3) 14(23.3) 6(10) 
 
 
The clinicopathological parameters were compared with the 
molecular classification as follows. 
The age wise distribution of the 60 cases is given below. Table 8 and chart 4 
Table 8: Age wise distribution of breast cancers in molecular 
classification 
 AGE (YEARS) 
Molecular  
Classification 
20-29 
(% of 
MC) 
30-39 
(% of 
MC) 
40-49 
(% of 
MC) 
50-59 
(% of 
MC) 
60-69 
(% of 
MC) 
70-79 
(% of 
MC) 
Total  
Luminal A  0 1(4.5) 5(23) 9(40) 5(23) 2(9) 22 
Luminal B  0 1(20) 1(20) 2(40) 1(20) 0 5 
HER2 0 2(25) 3(38) 1(13) 2(25) 0 8 
Hybrid  0 0 2(40) 2(40) 1(20) 0 5 
Basal  2(14) 1(7) 4(29) 3(22) 3(22) 1(7) 14 
Unclassified  0 1(17) 2(33) 2(33) 1(17) 0 6 
Total  2(3.3) 6(10) 17(28) 19(32) 13(22) 3(5) 60 
Pearson chi 
square test 
0.923 
 
The most common age group affected by breast cancers are 50-59 
years. Among the molecular classification, the luminal A and  luminal B 
showedhigherincidence of breast cancer in 50-59 age group with 40% 
incidence, whereas as HER 2(23%) and basal types (20%)  had 
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ahigherincidence at an earlier age group of 40-49 years. Unclassified 
showed equal distribution of 33% among both age groups. The youngest age 
of presentation is at 26 years and oldest was 75 years old. There was no 
statistical significance associated with this comparison. (Table 8 and Cart 4) 
Among the 60 cases entered in this study it was found that left side 
(58%) of the breast was predominantly affected than the right (42%) as 
shown in Table 9 and Chart 5. 
Table 9: Distribution of side of involvement in molecular classification 
 SIDE 
Molecular  
Classification (MC) 
Right  
(% of MC) 
Left  
(% of MC) 
Total  
Luminal A  10(46) 12(55) 22 
Luminal B  2(40) 3(60) 5 
HER2 1(13) 7(82) 8 
Hybrid  3(60) 2(40) 5 
Basal  6(43) 8(57) 14 
Unclassified  3(50) 3(50) 6 
Total  25(42) 35(58) 60 
Pearsons chi square test 0.578 
 
On analysing the side of involvement it was found that left sided 
tumors were more than right in luminal A, luminal B, HER 2 and basal 
types with 55%, 60%, 82% and 57% respectively. Among 5 cases of Hybrid 
tumors 3(60%) were on right side and unclassified type showed equal 
distribution of cases on right and left side of the breast. This was not 
statistically significant.(Table 9 and Chart 5) 
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Chart 3: Distribution of Molecular Subtypes in the current study 
 
 
Chart 4: Age wise distribution of breast cancers in molecular 
classification 
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quadrant with 21.7%, lower outer quadrant with 10.0% and the least 
common site was the upper inner quadrant with 8.3%, as shown in the Table 
10 and Chart 6. 
Table 10: Association of tumor location with molecular classification. 
 
 TUMOR LOCATION 
Molecular  
Classification 
UOQ 
(% of MC) 
LOQ 
(% of MC) 
LIQ 
(% of MC) 
CQ 
(% of MC) 
Total  
Luminal A  11(50) 3(14) 4(18) 4(18) 22 
Luminal B  4(80) 0 0 1(20) 5 
HER2 5(63) 1(12) 0 2(25) 8 
Hybrid  4(80) 0 1(20) 0 5 
Basal  9(64) 0 0 5(36) 14 
Unclassified  3(50) 2(33) 0 1(17) 6 
Total  36(60) 6(10) 5(8) 13(22) 60 
Pearsons chi 
square test 
0.388 
 
Among the molecular classification, all the classes showed an 
increased incidence of the tumor to be located in the upper outer quadrant 
with luminal A constituting 50%, luminal B 80%, HER2 type 63%, hybrid 
cases 80%, basal type 64% and unclassified 50%, followed by the central 
quadrant. None of the hybrid cases were located in the central 
quadrant.Tumor location was not a statistically significant parameter.(Table 
10 and Chart 6) 
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Chart 5: Distribution of side of involvement in molecular classification 
 
 
Chart 6: Association of tumor location with molecular classification 
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The size of the tumor was categorised on the basis of TNM staging. 
Majority of cases (68.3%) had tumor size of 2-5 cm, 25.4% had tumors 
more than 5 cm and only 6.7% of cases had less than 2 cm sized tumor. This 
is shown in Table 11 and chart 7. 
 
Table11: Association of tumor size with molecular classification 
 SIZE  
Molecular  
Classification 
<2 cm  
(% of MC) 
2-5 cm 
(% of MC) 
>5cm 
(% of MC) 
Total  
Luminal A  2(9) 16(73) 4(18) 22 
Luminal B  0 3(60) 2(40) 5 
HER2 0 5(63) 3(37) 8 
Hybrid  0 4(80) 1(20) 5 
Basal  1(7) 10(72) 3(22) 14 
Unclassified  1(17) 3(50) 2(33) 6 
Total  4(7) 41(68) 15(25) 60 
Pearsons chi 
square test 
0.921  
 
All the 6 classes of molecular classification including the hybrid cases 
showed an increased incidence in tumors of size between 2cm and 5 cm. 
with 73% of luminal A, 72% of basal, 63% of HER 2, 18% of hybrid cases, 
60% of luminal B and 50% of unclassified types. None of the luminal B, 
HER 2 type and basal type tumors was of small size. About 40% of luminal 
B, 37% of HER2 type and 33% of unclassified types had tumors of more 
than 5 cm size.(Table 11 and chart 7)  
 Among the 369 cases of radical mastectomy, 30(50%) cases of IDC 
NST and 30 (50%)  cases of special variants which included medullary, 
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mucinous, metaplastic, apocrine, lobular and papillary each constituting 
8.3% of cases, were taken in the study. This is shown in the Table 12 and 
chart 8. 
 
Table 12: Association of histologic type with molecular 
classification. 
 HISTOLOGICAL TYPE 
 
Molecular  
Classification 
 
IDC 
NST 
(% of 
MC) 
 
Metaplastic 
(% of MC) 
 
Papillary 
(% of 
MC) 
 
Lobular 
(% of 
MC) 
 
Apocrine 
(% of 
MC) 
 
Medullary 
(% of 
MC) 
 
Mucinous 
(% of 
MC) 
 
 
Total  
Luminal A  6(27) 2(9) 5(23) 4(18) 0 1(5) 4(18) 22 
Luminal B  3(60) 1(20) 0 0 1(20) 0 0 5 
HER2 6(75) 1(13) 0 1(13) 0 0 0 8 
Hybrid  2(40) 0 0 0 2(40) 1(20) 0 5 
Basal  8(57) 0 0 0 2(14) 3(22) 1(7) 14 
Unclassified  5(83) 1(17) 0 0 0 0 0 6 
Total  30(50) 5(8) 5(8) 5(8) 5(8) 5(8) 5(8) 60 
Pearson chi 
square test 
0.064  
 
On analysing the molecular classification and its comparison with the 
histological types it was found that among the 30 cases of infiltrating ductal 
carcinoma NST, 6 were luminal A and HER2 type, 3 were luminal B, 8 
were basal, 5 were unclassified. 2 cases showed strong positivity of both 
HER2 and luminal markers and were considered as hybrid cases. Among 
the 30 cases of special variants 16 cases were luminal A, 2 case were 
luminal B and HER2, 6 were basal and 1 unclassified. 3 cases were found to 
express hybrid markers. 
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This shows that 72% of luminal A tumors belongs to histological 
variants of special types rather than infiltrating ductal carcinoma NST. 
Where as 40%, 25%, 42% and 16% of luminal B, HER 2, basal and 
unclassified types respectively belongs to variants. 
Among the 5 cases of luminal B, 3 cases (60%) of them were invasive 
ductal carcinoma no special type, one apocrine and one metaplastic (each 
20%). 
Among the 8 cases of HER2 type, 6 cases (75%) were IDC NST and 
the rest were metaplastic carcinoma and lobular carcinoma each one case.  
2 cases of apocrine and 1 case of medullary carcinoma showed 
expression of hybrid markers and rest 2 cases were IDC NST. 
Within the 14 cases of basal type, majority belongs to IDC NST 
(57%), followed by 3 cases (22%) of medullary, 2 cases (14%) of apocrine 
and 1 case (7%) of mucinous carcinoma. None of the metaplastic, lobular 
and papillary was basal. 
 None of the variants except 1 case of metaplastic carcinoma belongs 
to the unclassified type (penta negative) the rest (83%) were IDC NST.  
This comparison did not show any statistical significance.(Table 12 and 
Chart 8). 
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Chart 7: Association of tumor size with molecular classification 
 
 
Chart 8: Association of histologic type with molecular classification. 
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Breast carcinomas are graded according to The Modified Scarff 
Bloom Richardson‟s grading system. This study included grade I, II and III 
with 10 cases in each grade which is shown in Table 13 and Chart 9. 
 
Table 13: Association of histological grade with molecular classification. 
 GRADE  
Molecular  
Classification 
Special  
variants 
(% of MC) 
Grade I 
(% of MC) 
Grade II 
(% of MC) 
Grade III 
(% of MC) 
Total  
Luminal A  16(73) 2(9) 4(18) 0 22 
Luminal B  2(40) 1(20) 1(20) 1(20) 5 
HER2 2(25) 1(13) 1(13) 4(50) 8 
Hybrid  3(60) 0 2(40) 0 5 
Basal  6(43) 2(14) 2(14) 4(29) 14 
Unclassified  1(17) 4(68) 0 1(17) 6 
Total  30(50) 10(17) 10(17) 10(17) 60 
Pearsons chi 
square test 
0.013 
 
4 out of 8 cases (50%) of HER 2 type, 4 out of 14 cases (28%) of 
basal types were grade III tumors. Among luminal A tumors, (9%) were 
grade I and 4(18%) were grade II and none belonged to grade III tumors. 
Luminal B tumors had equal distribution of cases among the 3 grades with 1 
case in each grade. Among 5 hybrid cases, 2(40%) were grade II and other 
were special variants. Among the 6 unclassified cases 4(66%) of them were 
grade I tumors and only 1 case was grade III. This comparison had 
statistical significance with the p value of 0.01. (Table 13 and Chart 9) 
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 Associated lesions in the adjacent breast tissue were studied for all 
the 60 cases. The most common lesion associated was the fibrocystic 
disease constituting 73.3%, followed by ductal carcinoma in situ with 18.3 
%. The least common lesion associated was the sclerosing adenosis with 
8.3%. As shown in Table 14 and Chart 10. 
 
Table 14: Association of molecular classification with other associated 
lesions  
 
 
Associated lesions 
Molecular  
Classification 
Fibrocystic 
disease 
(% of MC) 
DCIS 
 
(% of MC) 
Sclerosing 
adenosis 
(% of MC) 
Total  
Luminal A  16(73) 5(23) 1(4) 22 
Luminal B  4(80) 0 1(20) 5 
HER2 5(63) 1(13) 2(25) 8 
Hybrid  4(80) 0 1(20) 5 
Basal  11(79) 3(21) 0 14 
Unclassified  4(67) 2(33) 0 6 
Total  44(73) 11(18) 5(8) 60 
Pearsons chi 
square test 
 
0.472 
 
    Fibrocystic disease was the most common associated lesion with all the 
classes of molecular classification comprising 73% of luminal A, 80% of 
luminal B and hybrid, 79% of basal, 67% of unclassified types, 63% of 
HER 2 type. 5 (45%) out of 11 cases  of ductal carcinoma in situ belongs to 
luminal A class followed by 27% and 18% of basal and unclassified types 
respectively. 
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Chart9: Association of histological grade with molecular classification. 
 
 
Chart10: Association of molecular classification with other associated 
lesions. 
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 5 cases showed sclerosing adenosis in the adjacent breast of which 1 
case from luminal A, luminal B and hybrid types and 2 cases from HER2 
types. Basal and unclassified types did not show any association with 
sclerosing adenosis. This has no statistical significance.(Table 14 and Chart 
10) 
Lymphovascular invasion considered to be an adverse prognostic 
factor was assessed in all 60 cases. It was present in 66.7% of cases and 
absent in 33.3% of cases as shown in in Table 15 and Chart 11. 
Table 15: Association of lymphovascular invasion with the molecular 
classification 
 Lymphovascular invasion 
Molecular  
Classification 
Present 
(% of MC) 
Absent   
(% of MC) 
Total  
Luminal A  13(59) 9(41) 22 
Luminal B  3(60) 2(40) 5 
HER2 7(88) 1(12) 8 
Hybrid  3(60) 2(40) 5 
Basal  11(79) 3(21) 14 
Unclassified  3(50) 3(50) 6 
Total  40(67) 20(33) 60 
Pearsons chi square test 0.553 
 
Among the different classes of molecular classification, all classes 
except unclassified type showed increased incidence of lymphovascular 
invasion. Especially the HER 2 and basal types in which 87% and 78% had 
respectively, whereas only 60% of luminal tumors and hybrid cases had 
lymphovascular invasion. Unclassified tumors had equal number of cases 
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with and without lymphovascular invasion. This parameter did not show any 
statistical significance. (Table 15 and Chart 11) 
Chart11: Association of lymphovascular invasion with the molecular 
classification. 
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lymphocytic infiltration. This parameter did not have any statistical 
significance. (Table 16 and Chart 12) 
Table 16: Association of lymphocytic infiltration with the molecular 
classification 
 Lymphocytic infiltration 
Molecular  
Classification 
Present 
(% of MC) 
Absent   
(% of MC) 
Total  
Luminal A  17(77) 5(23) 22 
Luminal B  4(80) 1(20) 5 
HER2 4(50) 4(50) 8 
Hybrid  4(80) 1(20) 5 
Basal  11(79) 3(21) 14 
Unclassified  4(67) 2(33) 6 
Total  44(73) 16(27) 60 
Pearsons chi square test 0.706 
 
 
Increased amount of necrosis indicates a bad prognosis. 10 cases 
(16.7%) showed presence of necrosis. Majority of the cases (83.3%) showed 
no evidence of necrosis as shown in the Table 17 and Chart 13. 
Luminal A tumors did not show evidence of necrosis. 38% of HER 2 
type and 40% of luminal B showed presence of necrosis. 20% of hybrid and 
basal types and 17% of unclassified type had necrosis. There was no 
statistical significance with this comparison. (Table 17 and Chart 13)  
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Table 17: Association of necrosis with the molecular 
classification. 
 
 
 
NECROSIS 
Molecular  
Classification 
Present 
(% of MC) 
Absent   
(% of MC) 
Total  
Luminal A  0 22(100) 22 
Luminal B  2(40) 3(60) 5 
HER2 3(38) 5(62) 8 
Hybrid  1(20) 4(80) 5 
Basal  3(21) 11(79) 14 
Unclassified  1(17) 5(83) 6 
Total  10(17) 50(83) 60 
Pearsons chi square test 0.104 
 
Involvement of skin is considered to be stage IV disease. In this study 
in 91.7% of cases, the skin was not involved. 8.3% of cases had 
involvement of skin as shown in Table 18 and Chart 14. 
Table 18: Association of skin involvement with the molecular 
classification. 
 Skin infiltration 
Molecular  
Classification 
Present 
(% of MC) 
Absent   
(% of MC) 
Total  
Luminal A  1(5) 21(95) 22 
Luminal B  0 5(100) 5 
HER2 0 8(100) 8 
Hybrid  1(20) 4(80) 5 
Basal  1(7) 13(93) 14 
Unclassified  2(33) 4(67) 6 
Total  5(8) 55(92) 60 
Pearsons chi square test 0.191 
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Chart 12: Association of lymphocytic infiltration with the molecular 
classification. 
 
 
Chart 13: Association of necrosis with the molecular classification.
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Out of 22 cases of luminal A only 1 case (4.5%) had skin 
involvement, none of the luminal B and HER 2 cases, 7% of basal and 20% 
of hybrid types showed involvement. Among the molecular subtypes the 
unclassified types had an increased incidence of skin involvement with 
40%. This comparison did not have any statistical significance.(Table 18 
and Chart 14) 
 5 cases (8.3%)did not show any lymphnode involvement. Majority of 
cases (35%) had lymph nodes positive between 4 and 9 nodes. 26% had 1 to 
3 nodes positive and 30% had more than 10 nodes positive.(Table 19, Chart 
19) 
Table 19: Association of lymph node involvement with molecular 
classification. 
 Number of Lymph nodes involved 
Molecular  
Classification 
Nil  
(% of MC) 
1-3 
(% of MC) 
4-9 
(% of MC) 
>9 
(% of MC) 
Total  
Luminal A  3(17) 9(40) 6(27) 4(18) 22(36.7) 
Luminal B  0 2(40) 2(40) 1(20) 5(8.30 
HER2 0 2(25) (25)2 4(50) 8(13.3) 
Hybrid  0 1(20) 3(60) 1(20) 5(8.3) 
Basal  0 2(14) 4(28) 8(56) 14(23.3) 
Unclassified  2(33) 0 4(67) 0 6(10) 
Total  5(8.3) 16(27) 21(35) 18(30) 60(100) 
Pearsons chi 
square test 
0.045 
 
Among the molecular classification only luminal A (5%) and 
unclassified types (3.3%) had cases without lymph node involvement. 
Among luminal A class only 18% had more than 10 nodes involved. 
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Luminal A, luminal B, hybrid and unclassified cases had more cases with 4-
9 nodes involvement. HER2 (50%) and basal types (57%) had more number 
of cases with more than 10 nodes involvement. None of the unclassified 
cases had nodal involvement of more than 10 nodes. Lymph node 
involvement had a statistical significance. (Table19 and Chart 15) 
Margin status is an important prognostic factor. In this study, 14 cases 
(23.3%) had involved margins, and 46 (76.7%) cases had margins free of 
tumor infiltration as shown in Table 20 and Chart 16. 
Table 20: Association of margin status with molecularclassification. 
 
 Margins  
Molecular  
Classification 
Present 
(% of MC) 
Absent   
(% of MC) 
Total  
Luminal A  3(14) 19(86) 22 
Luminal B  0 5(100) 35 
HER2 3(38) 5(63) 8 
Hybrid  1(20) 4(80) 5 
Basal  5(36) 9(64) 14 
Unclassified  2(33) 4(67) 6 
Total  14(23) 46(77) 60 
Pearsons chi square 
test 
0.399 
 
HER 2, basal and unclassified types showed increased incidence of 
involvement of margins, comprising of 38%, 36% and 33% respectively. 
Luminal B tumors did not show any margin involvement. Luminal A and 
hybrid tumors had lesser involvement of margins constituting 14 and 20% 
respectively. 
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Chart 14: Association of skin involvement with the molecular 
classification      
 
Chart 15: Association of lymph node involvement with molecular 
classification. 
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 On analysing the stage of the tumor, majority of cases presented with 
the stage II tumors, among which were 20% of Stage II A and 42% of stage 
II B. 17% of cases landed up in stage III A. There were 2 cases (3.3%) with 
Stage I and 1 case (1.7%) with stage IV as shown in Table 21 and Chart 17. 
Table 21: Association of molecular classification with stage of the 
tumor. 
 STAGE  
Molecular  
Classification 
I 
(% of 
MC) 
IIA 
(% of 
MC) 
IIB 
(% of 
MC) 
IIIA 
(% of 
MC) 
IIIB 
(% of 
MC) 
IIIC 
(% of 
MC) 
IV 
(% of 
MC) 
Total  
Luminal A  1(5) 6(28) 12(55) 2(9) 1(5) 0 0 22 
Luminal B  0 1(20) 2(40) 2(40) 0 0 0 5 
HER2 0 1 2(25) 5(63) 0 0 0 8 
Hybrid  0 0 0 3(60) 1(20) 1(20) 0 5 
Basal  0 3(21) 8(57) 2(14) 0 0 1(7) 14 
Unclassified  1(17) 1(17) 1(17) 3(50) 0 0 0 6 
Total  2(3) 12(20) 25(42) 17(28) 2(3) 1(2) 1(2) 60 
Pearson chi 
square test 
0.083  
 
Among the 22 cases of luminal A type tumors, 86% (18 cases with 
stage II and 1 case with stage I) of cases belonged to earlier stages (I&II) 
with only three cases (5%) in stage III. Luminal B and unclassified types 
had 40% and 50% respectively in stage IIIA tumors. HER 2type and 
unclassified types had tumors in stage IIIA but not beyond that. All the 5 
cases of hybrid types and 21% of basal types were in stage III. The one case 
that presented in stage IV belongs to the basal type. This did not have any 
statistical significance. 
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Chart 16: Association of margin status with molecularclassification. 
 
 
Chart 17: Association of molecular classification with stage of the 
tumor. 
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Hormone receptor analysis was done for all the 60 cases and their 
expression was analysed.  
Table 22: ER expression among molecular subtypes. 
 ER EXPRESSION 
Molecular  
Classification 
Negative 
(% of MC) 
Weakly  
positive 
(% of MC) 
Intermediate  
positive 
(% of MC) 
Strongly 
positive 
(% of MC) 
Total  
Luminal A  0 0 7(31) 15(69) 22 
Luminal B  0 2(40) 3(60) 0 5 
HER2 8(100) 0 0 0 8 
Hybrid  0 0 5(100) 0 5 
Basal  13(93) 1(7) 0 0 14 
Unclassified  6(100) 0 0 0 6 
Total  32(53) 3(5) 15(25) 15(20) 60 
Pearsons chi 
square test 
0.003 
 
Among the 22 luminal A cases, 69% showed strong positivity for 
estrogen receptor with a composite scoring of 7 and 8. (Annexure V). 31 % 
showed an intermediate positivity with a composite scoring of 4, 5, and 6. 
40% of luminal B showed weakly positivity and 60% had intermediate 
scoring. All cases of the HER2 and unclassified types, 93% of basal types 
were negative for hormone receptors. All the 5 cases of hybrid tumors 
showed intermediate staining. (Table 22 and Chart 18). This had a 
statistically significant value. 
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 Table 23: PR expression among molecular subtypes. 
 
 PR EXPRESSION 
Molecular  
Classification 
Negative 
(% of MC) 
Weakly  
positive 
(% of MC) 
Intermediate  
positive 
(% of MC) 
Strongly 
positive 
(% of MC) 
Total  
Luminal A  3(14) 0 6(27) 13(59) 22 
Luminal B  0 2(40) 2(40) 1(20) 5 
HER2 8(100) 0 0 0 8 
Hybrid  3(60) 0 2(40) 0 5 
Basal  13(93) 1(7) 0 0 14 
Unclassified  6(100) 0 0 0 6 
Total  33(55) 5(8.3) 8(13) 14(23)  
Pearsons chi 
square test 
0.001 
 
 
3 cases (14%) of luminal A was negative for PR expression, 27% 
with intermediate staining and 59% had strong nuclear expression. Among 
luminal B weak and intermediate staining was 40% each and 1 case (20%) 
had strong positivity. All the HER2 and unclassified types and 93% of basal 
types were negative. Among the 5 hybrid cases 3 were negative and 2 were 
intermediate. This comparison had statistical significance as shown in Table 
23 and Chart 19. 
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Chart18: ER expression among molecular subtypes. 
 
 
 
Chart19: PR expression among molecular subtypes. 
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Table 24: HER2 neu expression among molecular subtypes. 
 
 HER 2 neu EXPRESSION 
Molecular  
Classification 
0 
(% of MC) 
1+ 
(% of MC) 
2+ 
(% of MC) 
3+ 
(% of MC) 
 
Total  
Luminal A  21(95) 0 1(5) 0 22 
Luminal B  0 1(20) 3(60) 1(20) 5 
HER2 0 0 1(12) 7(88) 8 
Hybrid  0 0 0 5(100) 5 
Basal  12(86) 1(7) 1(7) 0 14 
Unclassified  5(83) 1(17) 0 0 6 
Total  38(63) 3 (5)  4(7) 15(25) 60 
Pearsons chi 
square test 
0.002 
 
 
All the luminal A types except one was negative for HER 2 neu, and 
the 1 case had 2+ cytoplasmic membrane positivity. Luminal B types had 20 
% of cases with 1+ and 2+ each, and 60% with strong 3+ positivity. 88% of 
HER2 had 3+ staining and rest 1 case (12%) had 2+ staining. All the hybrid 
cases were strongly positive (3+). 93% of basal were negative, and the rest 
7% (1 case) showed 2+ staining. 100% of unclassified were negative. (0 and 
1+). This is depicted in Table 24 and Chart 20.  
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Table 25: CK 5/6 expression among molecular subtypes. 
 
 CK 5/6 EXPRESSION 
Molecular  
Classification 
1+ 
 (% of 
MC) 
2+ 
(% of MC) 
3+ 
 (% of MC) 
4+ 
 (% of 
MC) 
Total  
Luminal A  18(82) 3(14) 1(4) 0 22 
Luminal B  2(40) 2(40) 1(20) 0 5 
HER2 5(63) 3(37) 0 0 8 
Hybrid  2(40) 2(40) 1(20) 0 5 
Basal  0 1(7) 5(36) 8(57) 14 
Unclassified  4(67) 2(33) 0 0 6 
Total  29(48) 11(18) 8(14) 12(20) 60 
Pearsons chi 
square test 
0.001 
 
On analysing the CK 5/6 expression, among luminal A type, 82% 
were negative, 14% had 2+ and 4% had 1+ staining. 40% of luminal B had 
negative and 2+ staining respectively and 1 case (20%) with 3+ staining. 
Among HER2 63% was negative and 37% had 2+ staining. 40% of hybrid 
cases had 1+ and 2+each, and 20% had 3+ staining. Among the basal cases 
57% had 4+ strong positivity, 36% with 3+  and 7% with 2+ staining. 67% 
of unclassified were negative and 33% showed 2+ positivity. Only basal 
types had 4+ staining. This comparison had statistical significance.(Table 25 
and Chart 21). 
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Chart 20: HER2 neu expression among molecular subtypes. 
 
 
 
Chart 21: CK 5/6 expression among molecular subtypes. 
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On comparing the proliferation index within the molecular subtypes, 
it was found that luminal B, HER 2, hybrid and basal types had high 
proliferation index of 100%, 75%, 80% and 85% respectively. 86% of 
luminal A tumors had a low proliferation index. Unclassified tumors had an 
equal proportion (50%) of low and high proliferation indices. (Table 26& 
Chart 22) 
 
Table 26: Comparison of proliferation index among molecular subtypes 
 PROLIFERATION INDEX 
Molecular  
Classification 
HIGH 
(% of MC) 
LOW 
(% of MC) 
Total  
Luminal A  3(14) 19(86) 22 
Luminal B  5(100) 0 5 
HER2 6(75) 2(25) 8 
Hybrid  4(80) 1(20) 5 
Basal  12(86) 2(14) 14 
Unclassified  3(50) 3(50) 6 
Total  33(55) 27(45) 60 
Pearsons chi square test 0.01 
 
 
The follow up was done for all cases for a minimum period of one 
year. Among the 60 cases, 47 cases (78%) were alive and healthy, 10 cases 
(16.7%) had recurrences and 3 cases (5%) were dead due to tumor 
complications. (Table 26 and Chart 23). 
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Table 27: Follow up of molecular subtypes of breast cancers. 
 FOLLOW UP 
Molecular  
Classification 
Alive 
&Healthy 
(% of MC) 
Alive & 
recurred 
(% of MC) 
DEAD 
(% of MC) 
Total  
Luminal A  21(95) 1(5) 0 22 
Luminal B  5(100) 0 0 5 
HER2 5(63) 2(25) 1(12) 8 
Hybrid  3(60) 1(20) 1(20) 5 
Basal  9(65) 4(28) 1(7) 14 
Unclassified  4(67) 2(33) 0 6 
Total  47(78) 10(17) 3(5) 60 
Pearsons chi 
square test 
0.265 
 
 
One case of luminal A (0.4%) and hybrid types (20%), 2 case of HER 
2(25%) and unclassified types (30%) and 4 cases of basal type (28%) had 
recurrence. One case in each HER2, hybrid and basal type died during the 
follow up period. Rest of the cases were alive and healthy. 
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Chart 22: Comparison of proliferation index among molecular subtypes
 
 
Chart 23: Follow up of molecular subtypes of breast cancers. 
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In this current study the same set of patients were given the 
histopathological classification and then subjected to 
immunohistochemical analysis and classified under molecular 
classification aiming targeted therapy to the patients. 
Mc nemar’s test and inter rater agreement: 
The aim of this test is to evaluate the inter rater agreement between 
the histopathological and molecular classification systems and to quantitate 
the agreement with the KAPPA value by using the 2x2 classification 
tables. 
Each subtype under the molecular classification is compared with 
histopathological classification which is divided as infiltrating ductal 
carcinoma no special types and special variants by using the 2x2 tables. P 
value and the inter rater agreement KAPPA value is derived and analysed. A 
negative KAPPA value indicates that the strength of agreement between 
these two classification systems is very poor. 
Negative agreement between these two classification systems helps in 
substantiating the use of targeted therapy based on molecular 
classification. 
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Table 28: Comparison of luminal A type with histopathological 
classification by Mc nemar’s test. 
 
 MOLECULAR CLASSIFICATION 
HPE 
CLASSIFICATION 
LUMINAL A Others  Total  
IDC NST 5 25 30 (50%) 
VARIANTS 17 13 30 (50%) 
Total  22 (36%) 38 (64%) 60 (100%) 
95% CI 7.51% to 35.26% 
Significance 
level 
P=0.2115 
Inter rater 
agreement- 
KAPPA value 
-0.367 
 
  
When Luminal A subtype was compared with the histological 
subtypes it was found that the P value was 0.2 and the KAPPA value was 
-0.367, which indicates that strength of agreement between these two 
systems was very poor and the agreement between them is worse than 
chance. These values are depicted in Table 28. 
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Table 29: Comparison of luminal B type with histopathological 
classification by Mc nemar’s test. 
 
 MOLECULAR CLASSIFICATION 
HPE 
CLASSIFICATION 
LUMINAL B Others  Total  
IDC NST 2 28 30 
VARIANTS 3 27 30 
Total  5 55 60 
95% CI 25.05% to 49.56%   
Significance 
level 
P < 0.0001   
Inter rater 
agreement- 
KAPPA value 
-0.0333   
 
  
On comparing the Luminal B and histological classification, it had a 
significant P value of <0.0001 and the inter rater agreement KAPPA value 
was -0.033. This negative value proves the disagreement between these two 
systems. This is illustrated in the Table 29. 
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Table 30: Comparison of HER 2 type with histopathological 
classification by Mc nemar’s test. 
 
 
 
MOLECULAR CLASSIFICATION 
HPE 
CLASSIFICATION 
HER 2 Others  Total  
IDC NST 6 24 30 (50%) 
VARIANTS 2 28 30 (50%) 
Total  8 (13%) 52 (86%) 60 (100%) 
95% CI 28.6% to 40%   
Significance 
level 
P < 0.0001   
Inter rater 
agreement- 
KAPPA value 
-0.200   
 
 
On comparing the HER 2 subtype and histological classification, it 
was found that it had a significant P value of <0.0001 and the inter rater 
agreement KAPPA value was -0.200. This negative value proves the 
agreement between these two systems are worse than chance. This is 
illustrated in the Table30. 
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Table 31: Comparison of Hybrid type with histopathological 
classification by Mc nemar’s test. 
 
 MOLECULAR CLASSIFICATION 
HPE 
CLASSIFICATION 
Hybrid  Others  Total  
IDC NST 2 28 30 (50%) 
VARIANTS 3 27 30 (50%) 
Total  5 (8.3%) 55 (91.7%) 60 (100%) 
95% CI 25.05% to 49.56%   
Significance 
level 
P < 0.0001   
Inter rater 
agreement- 
KAPPA value 
-0.0333   
 
 
On comparing the Hybrid subtype with the histopathological 
classification, it was found that it had a significant P value of <0.0001 and 
the inter rater agreement KAPPA value was -0.033. This negative value 
proves the disagreement between these two systems. This is illustrated in 
the Table31. 
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Table 32: Comparison of Basal type with histopathological 
classification by Mc nemar’s test. 
 
 MOLECULAR CLASSIFICATION 
HPE 
CLASSIFICATION 
BASAL Others  Total  
IDC NST 9 21 30 (50%) 
VARIANTS 5 25 30 (50%) 
Total  14 (23.3%) 46 (76.7%) 60 (100%) 
95% CI 4.79% to 36.69%   
Significance 
level 
P = 0.0140   
Inter rater 
agreement- 
KAPPA value 
-0.0346   
 
 
On comparing the Basal subtype with the histopathological 
classification, it was found that it had a significant P value of 0.01 and the 
inter rater agreement KAPPA value was -0.034. This negative value proves 
the disagreement between these two systems and agreement if any, is worse 
than chance. This is illustrated in the Table 32. 
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Table 33: Comparison of Unclassified type with histopathological 
classification by Mc nemar’s test. 
 
 MOLECULAR CLASSIFICATION 
HPE 
CLASSIFICATION 
UNCLASSIFIED Others  Total  
IDC NST 5 25 30 (50%) 
VARIANTS 1 29 30 (50%) 
Total  6 (10%) 54 (90%) 60 (100%) 
95% CI 23.14% to 44.18%   
Significance 
level 
P < 0.0001   
Inter rater 
agreement- 
KAPPA value 
-0.100 
  
 
On comparing the unclassified subtype with the histopathological 
classification, it was found that it had a significant P value of <0.0001 and 
the inter rater agreement KAPPA value was -0.100. This negative value 
proves the disagreement between these two systems. This is illustrated in 
the Table 33. 
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Figure 10: Invasive ductal carcinoma NST         Figure11: Malignant ductal epithelial cells     
tubule formations in >75% tumor cells.              with mild nuclear pleomorphism & low 
HPE 3765/13, 40x                                                   mitosis. HPE 3765/13, 400x 
   
 
 
INVASIVE DUCTAL CARCINOMA NOS GRADE 2 
         
Figure 12: Sheets of malignant ductal                  Figure 13: Malignant ductal epithelial cells 
epithelial cells, 30% tubule formation.                 in sheets, 30% tubules and mild nuclear 
HPE 3446/13, 100x                                                  pleomorphism. HPE 3446/13, 400x 
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Figure 14: Malignant ductal epithelial cells       Figure 15: Malignant ductal epithelial cells 
in sheets. HPE 5379/13, 100x                               with no tubules, marked nuclear,     
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Figure 16: Tumor nests floating in mucin.         Figure 17: Malignant ductal epithelial 
HPE 4653/12, (100x)                                             cells with mild nuclear pleomorphism 
                                                                                and no mitosis. HPE 4653/12, (400x) 
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    Figure 18: Tumor cells arranged in               Figure 19: Tumor cells arranged in 
    lobular pattern with pagetoid spread            singles in Indian file pattern. 
    around ductal elements.                                  HPE 3467/12, (400X) 
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Figure 20: Tumor cells in syncytial  
pattern with marked nuclear  
pleomorphism and prominent nucleoli. 
HPE 8213/12 (400X) 
Figure 21: Nodular arrangement of tumor  
cells with lymphoplasmacytic infiltrate in            
periphery. HPE 8213/12 (100X)                    
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Figure 22: Tumor cells in papillary                    Figure 23: Tumor cells in delicate 
pattern. HPE 1523/12 (100x)                               papillary pattern. HPE 1523/12 (400x) 
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Figure 24 Apocrine cells in papillary 
pattern. HPE 6973/11 (100x) 
  
 
 
Figure 25: Apocrine cells with abundant 
granular eosinophilic cytoplasm. (400x) 
HPE 6973/11 
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Figure 26: Nests of tumor cells with 
spindle cell differentiation. 
HPE 5451/11 (100x) 
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Figure 28: Metastatic deposit in node 
(100x). HPE 8469/13. 
 
Figure 27: Squamous cell nests in between 
the tumour cells. HPE 5451/11 (400x) 
Figure 29: Lymphatic invasion.  
(100x). HPE 8407/13. 
  
 
 
 
 
 
 
 
       
 
Figure 30: Vascular invasion (400x) 
                  HPE 8552/13 
   
 
 
 
 
 
 
 
 
 
       
 
Figure 32: Necrosis. HPE 7164/13. 
                            (400x)  
 
Figure 31: Lymphocytic infiltration. 
           (400x) HPE 8213/12 
Figure 33: Skin infiltration  
HPE 8593/13. (100X). 
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 Figure 34: Invasive ductal carcinoma NST.             
 Negative nuclear staining for estrogen  
 receptor. HPE NO: 2351/13 
Figure 35: Invasie ductal carcinoma NST.              
Positie nuclear staining (5+3) for  
estrogen receptor. HPE NO: 7173/13 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 37: Invasie ductal carcinoma NST.              
Positive nuclear staining (5+3) for  
estrogen receptor.HPE NO: 7173/13 
 
 
 
 
 
 
 
 
 
Figure 36: Invasive ductal carcinoma NST.              
Negative nuclear staining (1+1) for  
estrogen receptor.HPE NO: 7173/13 
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Figure 38: Invasive ductal carcinoma NOS  
Negative cytoplasmic staining of HER 2 neu   
HPE NO: 6959/13 
 
Figure 39: Invasive ductal carcinoma NOS  
Positive (3+) cytoplasmic staining of 
HER 2 neu, HPE NO: 3428/13 
 
Figure 41: Invasive ductal carcinoma NST  
Positive (4+) nuclear staining of 
CK 5/6, HPE NO: 2778/13 
 
Figure 40: Invasive ductal carcinoma NST  
Negative nuclear staining of 
CK 5/6, HPE NO: 7891/11 
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Figure 43: Invasive ductal carcinoma NST  
High proliferation index (>14%); nuclear 
staining of Ki67. HPE NO: 2778/13 
 
Figure 42: Invasive ductal carcinoma NST  
Low proliferation index (<14%); nuclear 
staining of Ki67. HPE NO: 2351/13 
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Figure 45: ER –Nuclear staining (5+3), 
400x  
Figure 46: PR –Nuclear staining 
(2+3), 100x  
Figure 47: HER 2 Neu; cytoplasmic 
membrane positivity; 1+ Negative, 
400x. 
Figure 48: CK 5/6 – Negative, 400x. Figure 49: KI 67- Low proliferation 
index, 400x 
Figure 44: Invasive ductal 
carcinoma NST 
H&E, 100x. 
LUMINAL B – HPE NO: 7478/13 
 
 
                                                             
 
 
 
      
 
 
 
      
 
 
 Figure 51: ER –Positive, 3+3, 100x 
 Figure 52:  PR –Positive; 2+1,100x  
Figure 50: Apocrine carcinoma, H&E, 
400x 
Figure 53: HER 2 NEU; cytoplasmic 
membrane positivity; 1+ Negative, 400x 
Figure 54: CK 5/6 –Negative, 400x. 
 
 
 
Figure 55: KI 67- High proliferation 
index. 100x 
 HER 2 TYPE- HPE NO: 5601/13 
 
 
      
 
 
      
 
 
 
      
 
Figure 57: ER –Negative; 0+0, 100x  
Figure 58: PR –Negative; 0+0, 100x Figure 59: HER 2NEU–cytoplasmic 
membrane positivity; 3+, 400x 
Figure 60: CK 5/6 – Negative, 100x 
 
 
 
Figure 61: KI 67- High proliferation 
index, 100x 
Figure 56: Invasive ductal carcinoma NST. 
H&E, 100x. 
HYBRID TYPE- HPE NO: 3446/13 
 
 
          
 
 
 
      
 
 
 
                                                              
 
 
Figure 62: Invasive ductal carcinoma  
NST H&E, 400x 
. 
Figure 63: ER –Nuclear staining; 5+3, 
100x 
  Figure 64:  PR –Positive; 2+1,400x  Figure 65: HER 2NEU–cytoplasmic 
membrane positivity; 3+, 400x 
Figure 66: CK 5/6 – Negative, 400x. 
 
 
 
Figure 67: Ki 67- High proliferation 
index, 100x 
BASAL TYPE- HPE NO: 1696/12 
 
 
      
 
 
 
      
 
 
       
 
 
Figure 69: ER –Negative; 0+0, 400x 
Figure 70: PR –Negative; 0+0,400x  Figure 71: HER2 neu –Negative; 400x 
Figure 68: Medullary carcinoma, 
H&E, 100x 
   Figure 72: CK 5/6; 4+ positive, 400x. Figure 73: Ki67- High proliferation 
index, 400x. 
UNCLASSIFIED–HPE NO: 8828/13 
 
 
            
 
 
 
            
 
 
                                               
Figure 79: Ki67- High proliferation 
index, 400x 
Figure 78: CK 5/6 – Negative, 400x. 
 
 
 
Figure 75: ER – Negative; 0+0, 400x 
   Figure 76: PR – Negative; 0+0, 400x   Figure77: HER2 neu–Negative; 400x 
Figure 74: Invasive ductal carcinoma 
NST H&E, 400x 
. 
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DISCUSSION 
Breast carcinoma is one of the most commonly diagnosed cancers in 
females worldwide, comprising 16% of all female cancer cases. 
[1] 
Its 
incidence in India is 30-33% per 1,00,000 women and the relative risk is 
0.033(1 in 30).
 [2] 
Early diagnosis and treatment will certainly reduce the 
mortality rates. 
In this current study, immunohistochemical analysis was done for 60 
cases of breast carcinomas, evaluated and scoring given as per ASCO –CAP 
guidelines. Based on the scoring those cases were classified as molecular 
subtypes. A comparative analysis of molecular classification with the 
clinical parameters, histological type, grade and prognostic factors were 
made. 
Madras Medical College being a tertiary referral centre, in the study 
period, the relative frequency of breast cancers among the other surgical 
cases was 3.85%. Among the entire breast specimens received for 
histopathological examination, 46.11% of the cases were reported to be 
malignant. 
60 cases of breast carcinomas were classified under molecular 
classification, based on the immunohistochemical markers. The most 
common was found to be the luminal A type comprising 37% and the least 
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common was the luminal B and hybrid types each comprising 8%. This was 
in concurrence with the study done by Perou and sorlie et al. 
[7] 
The age of breast cancer patients ranged from 25 to 85 years with a 
mean age of 51.7 years. The highest incidence of breast cancer occurred in 
50 to 59 year age group. This is in concurrence with the study done by 
Rajesh Singh Laishramet al.
[127] 
Among the molecular classification the 
HER 2 and basal types had cases at an earlier age of presentation. This was 
in concurrence with the study done by Lajos Pusztai et al
[124,125]
. 
 It was found that luminal A, luminal B, HER2 and basal types had 
more number of left sided tumors. Hybrid type had more right sided tumors. 
All the molecular subtypes showed an increase incidence of tumor located 
in the upper outer quadrant followed by central quadrant tumors. 
Ahigherproportion of T2 sized tumors (68.3%) were seen (Table 25) 
similar to the study of Christine L. Carteret al (USA), 
[128]
and Lakmini et al 
(India).
[130] 
Table 34: Comparison of size of tumors 
Size  Christine L. 
Carter et al
128 
F S Al-Joudi 
et al
129 
Lakmini 
et al
130 
Current 
study 
T1 33.6 3.14 14.5 6.7 
T2 55.4 19.37 74 68.3 
T3 11 77.49 11.5 25 
3 
 
Luminal B, HER 2 and unclassified types had tumors of T3 size of 
more than 5 cm. Majority of luminal A tumors were of T2 size. This was in 
concurrence with the study of bhumsukkaen et al. 
The comparison of histological classification and the molecular 
classification shows that 72% of luminal A tumors belongs to histological 
variants of special types rather than infiltrating ductal carcinoma NST. 
Whereas 40%, 25%, 42% and 16% of luminal B, HER 2, basal and 
unclassified types respectively belongs to variants. 
Among the 5 cases of mucinous tumors all except one were hormone 
receptor positive and all 5 were HER 2 negative. This was in concurrence 
with the study of Lacorixtriki et al.
 [132] 
(Table 35) 
Table35: Immunohistochemical analysis of Mucinous carcinoma 
IHC IN MUCINOUS 
CARCINOMAS 
LACORIX TRIKI ET 
AL
[132] 
CURRENT STUDY 
ER, PR positive 86% 80% 
HER2 neu negative 96% 100% 
 
Among the 5 cases of medullary tumors, 3 (60%) were triple 
negative, those were negative for both hormone receptors and HER 2 neu. 
This was in concurrence with the study of Jensen et al. 
[131]
(Table 36) 
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Table36: Immunohistochemical analysis of Medullary carcinoma 
IHC IN MEULLARY 
CARCINOMAS 
JENSEN ET AL CURRENT STUDY 
ER, PR positive 12% 20% 
HER2 neu 22% 20% 
Triple negative 76% 60% 
 
All the 5 cases of papillary carcinomas belonged to luminal A and 
were positive for hormonal receptors and negative for HER 2 neu. Similar 
results were produced in the study of Chen et al
[134]
 and Lotan et al
[135]
 
(Table 37) 
 
Table37: Immunohistochemical analysis of papillary carcinoma
 
IHC in papillary 
carcinoma of 
breast 
Chen et al
[134] 
Lotan et al
[135] 
Current study 
ER,PR positive 84.8% 89.5% 100% 
HER 2 neu 
positive 
0% 15.8% 0% 
 
Among the 5 cases of apocrine carcinomas none was luminal A. one 
case was luminal B and 2 cases were basal and hybrid tumors. This was in 
concurrence with the study done by Matsuo et al.
[136]
 (Table 38) 
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Table38: Immunohistochemical analysis of apocrine carcinoma 
IHC in apocrine 
carcinoma of 
breast 
Matsuo et al
[134] 
Current study 
ER,PR positive 17% 20% 
HER 2 neu 
positive 
33% 40% 
Triple negative 46% 40% 
 
Metaplastic carcinomas were described as triple negative tumors in 
the study done by GM Tse et al 
[138]
. But surprisingly in the current study, 
among the 5 cases of metaplastic tumors none belonged to the basal types. 2 
were luminal A, one was luminal B type, one was HER 2 and one was 
unclassified. (Table 39) 
 
Table39: Immunohistochemical analysis of Metaplastic 
carcinoma 
IHC in metaplastic  
carcinoma of breast 
GM Tse  et al 
[138] 
Current study 
ER, PR positive 8.8% 40% 
HER 2 positive 0% 20% 
Triple negative 93% 0% 
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Among the 5 cases of lobular carcinoma, 80% of them was luminal A 
tumors. This was in concurrence with the study done by Weidner et al 
[139]
 
(Table 40) 
Table40: Immunohistochemical analysis of Lobular carcinoma 
IHC in lobular carcinoma 
 
Weidner et al 
[139] 
Current study 
ER,PR positive 86% 80% 
HER 2 positive 08% 20% 
Triple negative 06% 0% 
 
 In the literature, studies have shown the most common of molecular 
subtypes was luminal A, followed by luminal B, least was HER 2 and basal 
type 
[140,141,142,143]
. But to the contradiction in the current study, among the 30 
cases of invasive ductal carcinoma, most common molecular subtype was 
basal, followed by luminal A and HER 2 type. (Table 41). 
Table41: Immunohistochemical analysis of invasive ductal carcinoma. 
IHC IN 
INVASIVE 
DUCTAL 
CARCINOMA 
Constantinidou  
et al
140 
Correa 
Geyer et 
al
141
  
Rebecca 
dent et al
 
Perou et 
al
143 
Current 
study 
ER, PR 
positive 
65% 72% 56% 62% 30% 
HER2 positive 15% 22% 18% !4% 20% 
Tiple negative 
Ck5/6 positive 
26% 28% 11.2% 15% 36% 
Unclassified   14%  15% 14% 
 
7 
 
 In the current study, 40% of grade I tumors were unclassified type. 
50% of basal and 29% of HER 2 type tumors belonged to high grade (grade 
III). 18% of luminal A tumors were grade II tumors. None of the luminal A 
and hybrid types was grade III. 
In the study of rakha et al they have concluded that among the ER 
positive Luminal A tumors, there was a considerable difference in their 
hazard ratio and ten year risk of relapse. It was found that hazard ratio has 
increased with an increase in the grade of the tumour. 10 year risk of relapse 
was 5% for grade 1 tumours, 24% for grade II tumours and 43% for grade 
III tumours, with a statistical significance. 
In this current study, 27 cases of luminal tumours were graded as 
11% of grade I, 22% of grade II and 5% of grade III tumours. After one year 
of follow up period these tumours there was an increased incidence of 
recurrence rate reported in grade III tumors. Also this study shows that the 
HER2 and basal types had more number of grade III tumors. This was in 
concurrence with the study done by Rakha et al. (Table 42) 
Table 42: Comparison of grade with the recurrence. 
 Rakha et al 
(% of risk of relapse) 
Current study 
(% of recurrence and dead) 
Grade I 5% 3.3% 
Grade II 24% 6.6% 
Grade III 43% 16.7% 
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Fibrocystic disease was the most common associated lesion with all 
the molecular subtypes. Ductal carcinoma in situ was more frequently 
associated with unclassified types. All classes of molecular classification 
showed an increased incidence of lymphovascular invasion. HER2 and 
basal types showed increase percentage of lymphovascular invasion. 
Luminal tumors had lesser percentage. This gives a better prognostic 
significance of luminal tumors and adverse for HER 2and basal types. This 
was in concurrence with the study done by Cheang Maggie et al
[148]
. 
Table 43: Comparison of lymphovascular invasion with molecular 
classification. 
 Cheang Maggie et al
[148]
 
(% of cases with 
lymphovascular 
invasion) 
Current study 
(% of cases with 
lymphovascular 
invasion) 
Luminal A 39% 59% 
Luminal B 50% 60% 
HER 2 type 60% 88% 
Basal  64% 79% 
 
 In their study they have also shown the percentage of lymph nodal 
involvement which was in concurrence with the current study. HER2 and 
basal types showed increased incidence of tumors with N3 nodal 
stage.(Table 44) 
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Table 44: Comparison of lymph node involvement with the molecular 
classification 
 Cheang Maggie et al
[148]
 
(no. of nodes involved) 
Current study 
(no. of nodes involved) 
 Nil  1-3 >4 Nil  1-3 >4 
Luminal A 55% 28%     11% 17% 40% 45% 
Luminal B 28% 28% 28% 0 40% 60% 
HER 2 
type 
11% 16% 24% 0 25% 75% 
Basal  10% 22% 28% 0 14% 86% 
 
Most of the tumors had lymphocytic infiltration, especially the 
luminal tumors showed an increased incidence. The other prognostic factors 
like necrosis, skin infiltration and involvement of margins were 
predominantly associated with luminal B, HER2 type and the basal types. 
Table 45: Comparison of distribution of AJCC staging in breast 
cancers 
 
 Rajesh 
singhlaishram
[127] 
(%) 
Carey et al
[146] 
(%) 
Current study 
(%) 
Stage I 3.3 39 3 
Stage II 12.3 51 62 
Stage III 76.4 8 34 
Stage IV 7.8 3 2 
 
Most of the cases presented in stage II followed by stage III which 
was similar to the study of Carey et al.  Rajesh Singh Laishram et al
[127] 
who 
studied 142 breast cancers in Manipur and reported the increased incidence 
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ofhigherstage tumors in their population when compared to the western 
studies done by  Carey et al
[146]
(Table 46). In this study it was found that 
HER2 and basal types had tumors withhigherstage. 
Table 46: Comparison of KI67 index in hormone receptor 
positive tumors and its relapse free survival. 
Ki 67 index in 
hormone receptor 
positive tumors 
Cheang et al.
[147] 
(10 year relapse free 
survival) 
Current study. 
(1 year relapse free 
survival) 
High  42% 61% 
Low 69% 100% 
 
In the current study those hormone receptor positive tumors with high 
proliferation were considered as luminal B category. This was similar to the 
study of Bentran and Philippe bedard et al  in which they have concluded 
that although both luminal A and luminal B tumours express estrogen 
receptor positivity, the luminal B  subtype end up with early relapse when 
treated with endocrine therapy compared to the luminal A subtypes. Early 
distant metastases were identified in luminal B subtypes with a hazard ratio 
of 2.86 when compared to 1 of luminal A tumours. This has led to the 
identification and segregation of aggressive luminal B tumours from the 
indolent luminal A tumours, as those tumours with reduced hormonal 
receptor expression, variable HER 2 expression and high proliferation 
index.  
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According to Maggie cheang et al
[148]
 in their study of breast cancers 
found that among the ER positive cancers that expressing high proliferation 
index with ki67,  a nuclear marker for cell proliferation gained minimally 
with adjuvant chemotherapy and were associated with worst outcomes 
irrespective of their histological and molecular subtypes. Ki67 index was 
given a visually assessable cut-off point of 14 % and its prognostic 
significance was assessed 
[148]
. 
Beyond the three biomarkers it is essential to have Ki 67 proliferation 
index to categorise luminal B tumours which are generally tamoxifen 
resistant.This is an effort to improve survival in these patients and 
development of novel therapeutic agents that will alter the natural course of 
the illness. (Table 47) 
Table 47: Comparison of number of basal tumors among the 
triple negative tumors 
 Cheang et al
[147] 
(%) 
SeemaSethi et al 
(%) 
Current Study 
(%) 
Triple negative 
tumors 
17% 24% 33% 
CK 5/6 positive 
tumors 
9% 24% 23% 
 
According to cheang et al 
[147]
, they have concluded that the expanded 
immunopanel of five markers which composed of ER, PR, HER2neu, 
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EGFR, and CK 5/6 than the usual triple biomarkers of ER, PR and 
HER2neu provides a better definition of basal like tumours and its disease 
free survival more specifically. They have found that not all the triple 
negative tumors express the basal markers.  Only 9% out of 17% of triple 
negative tumors expressed basal markers.  This similar finding was found in 
the current study, in which among 33% of triple negative tumors only 23% 
showed positivity for basal markers. Another study of seemaseethi showed 
that all cases of triple negative tumors expressed basal markers. 
Triple negative tumours which are considered to have poor outcome 
where conferred as basal type but those cohort of triple negative tumours 
with positive basal markers are found to have almost entirely and 
significantly bad outcome. The significance of demonstrating the basal type 
tumours is that they may benefit from EGFR targeted therapy and specified 
chemotherapy. 
Table 48: Comparison of CK5/6 expression among molecular 
classification. 
 Seemasethi et al
[149] 
(EGFR, CK 5/6 
expression ) 
Current study
 
(CK 5/6 expression ) 
Luminal A 0 5% 
Luminal B 2% 20% 
HER 2 type 3% 0 
Basal  100% 92.8% 
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 In the current study it was found that the basal type tumors had the 
highest expression of CK5/6 expression. This was concurrent with the study 
done by Seemasethi et al
[149]
 who has found that epithelial to mesenchymal 
transition occurs during the development of carcinogenesis, resulting in 
increased metastatic potential of the tumour cells and resistance to the 
therapy. Expression of vimentin, EGFR, CK5/6 are involved in this 
trasnsition. In this study they have concluded that these markers were 
statistically significantly expressed in triple negative tumours when 
compared to luminal A and luminal B and consistently reflected the 
aggressiveness of the tumour. 
Under the umbrella of triple negative tumours which has an overall 
poor survival and early recurrence, there are tumours with good prognosis 
as adenoid cystic carcinoma and secretory carcinoma. So it is essential to 
subtype triple negative tumours with basal markers. This is concluded in 
this study by constantindou et al 
[140]
. 
Table 49: Cancer specific survival among molecular classification 
 Maggie cheang et 
al.
[147]
(cancer 
specific survival) 
Current 
study.(cancer 
specific survival) 
Luminal A 79% 93% 
Luminal B 64% 100% 
Hybrid 57% 60% 
Basal   62% 
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 Luminal B and hybrid types had an increased incidence of 
recurrence in the study of Maggie cheang et al 
[147]
. In their study of 
immunohistochemical analysis of breast cancers have concluded that all the 
luminal B and luminal -HER 2 hybrid tumours were associated with poor 
recurrence free survival and disease survival, those who were treated with 
adjuvant systemic therapy. But in the current study, after the one year 
follow up period it was found that all he luminal B tumors were alive and 
healthy, whereas the luminal-HER2 hybrid and basal types had only 60% of 
cases with disease free survival.Therefore it is essential to identify the basal 
tumours and hybrid categories so that they are provided with additional 
therapies. 
Treatment for breast cancers, given based on the histopathological 
classification is broad based and includes endocrine therapy, systemic 
chemotherapy and Herceptintherapy. Whereas when breast cancers were 
classified under molecular classification a better targeted therapy is 
provided, avoiding unnecessary drugs to patients who do not need it, 
thereby preventing unnecessary drug related toxicities and reducing the 
costs of the treatment. 
There exist a difference in the treatment options between the 
histopathological classification and molecular classification. Therefore it is 
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necessary to prove the disagreement between these two classification 
systems. 
In this current study, each molecular subtype was compared with the 
histopathological classification and it was found that all the subtypes had a 
disagreement with the histopathological classification that was proved by 
the negative inter rater agreement KAPPA value. Disagreement between the 
two systems substantiates the value of molecular classification in the field of 
targeted therapy. 
In the current study the treatment was given for some cases based on 
the histopathological classification and for some based on the 
immunohistochemical analysis of triple markers. In other studies of Hess 
KR et al
[150]
, Ayers M et al
[151]
, Gianni L et al
[152]
,they have found a 
significant reduction in the incidence of relapse, when treatment was  
targeted therapy  based on molecular classification.  
LIMITATIONS OF THE STUDY 
 The cases were selected on the basis of histopathological 
classification in the tertiary care centre and not a population 
base study, which will not reflect the true prevalence of the 
general population 
 Her 2 neu expression has an intermediate stain scoring of 2+ 
which requires FISH for grading it as negative or positive. 
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 Gene expression profiling will give more accurate molecular 
subtypes than immunohistochemistry, but being expensive it 
cannot be applied to all patients. 
 Being a retrospective study the targeted therapy according to 
molecular classification was not given and hence the 
prognostic inference could not be ascertained. 
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SUMMARY 
This study is a prospective and retrospective descriptive study of 
invasive breast cancers conducted in the Institute of Pathology, Madras 
Medical College, Chennai during the period between Jan 2011 to Jun 2013. 
A total of 26,536 specimens were received. Total numbers of breast 
specimens received were 1412 cases, of these breast tumours accounted for 
1023 cases with a percentage of 3.85% of all cases (including both 
incisional and excisional biopsies). The total number of non-neoplastic, 
benign and malignant cases was 289, 472 and 651 respectively. Thus the 
distribution of non-neoplastic breast lesions was 20.46%, benign tumours 
were 33.42% and of malignant tumours were 46.11%. Of these, a total of 
369 mastectomy specimens (simple, modified radical or radical 
mastectomy) were received. All invasive breast carcinomas no special type 
(ductal and lobular), medullary, mucinous, papillary, apocrine and 
metaplastic carcinomas irrespective of the age and sex were included for the 
study 
Detailed history of the cases regarding age, sex, side of the breast, 
type of procedure, history of neo adjuvant therapy, details of gross 
characteristics such as tumour size, nodal status details were obtained for 
those 60 cases included in the study. 10 cases of each grade from Invasive 
ductal carcinoma NOS subtype  and 5 cases from special type as medullary, 
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metaplastic, mucinous, apocrine, papillary and invasive lobular were 
randomly selected from the total cases. Samples were subjected to 
immunohistochemical analysis of 5 markers which includes 
ER,PR,H2N,CK5/6 and Ki67. Slides were evaluated and scoring was given. 
Based on which they were classified into luminal A, luminal B, HER 2 , 
basal and normal like/ unclassified as per molecular classification.  
 
LUMINAL A TYPE 
 Most common age group is 50 -59 years (40%). 
 Most common on the left side. 
 The tumor was commonly located in the UOQ (50%). 
 The tumor size commonly ranged between 2cm and 5 cm. (73%) 
 Most of the tumors in Luminal A group were the histological special 
variants (73%). Among which, papillary constituted 23%. 
 Among the IDC NST tumors, grade II (18%) was the most common 
grade. 
 The most common associated lesion was fibrocystic disease (73%). 
 59% of the tumors showed lymphovascular invasion. 
 77% of the tumors showed lymphocytic infiltration. 
 None of the cases had necrosis. 
 Only 5% of the tumors showed skin involvement. 
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 40% of the tumors had N2 stage of nodal involvement. 17% of the 
cases did not have lymph node involvement. 
 14% of the cases showed involvement of margins. 
 Most of the tumors belonged to Stage II (83%). 
 69%  and 59% of the tumors showed strong ER and PR expression 
respectively. 
 Only 5% expressed HER2 neu positivity. (2+) 
 82% of the tumors did not express CK5/6. 
 86% of the tumors had low proliferation index with Ki-67. 
 On follow up, 95% of cases were alive and healthy and one case had 
recurrence. 
 By McNemar’s test, the comparison of Luminal A type with the 
histopathological classification showed an inter rater agreement 
Kappa value of – 0.367 which indicates disagreement. 
 
LUMINAL B TYPE 
 Most common age group is 50 -59 years (40%). 
 Most common on the left side. 
 The tumor was commonly located in the UOQ (80%). 
 The tumor size commonly ranged between 2cm and 5 cm (60%). 
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 Most of the tumors in Luminal B group were infiltrating ductal 
carcinoma NST (60%). 
 Among the variants, one case of metaplastic carcinoma and one case 
of apocrine carcinoma belonged to Luminal B group. 
  Among the IDC NST tumors, all the grades were of equal proportion. 
 The most common associated lesion was fibrocystic disease (80%). 
 60% of the tumors showed lymphovascular invasion. 
 80% of the tumors showed lymphocytic infiltration. 
 40% of the cases had necrosis. 
 None of them showed skin involvement. 
 40% of the tumors exhibited N1 and N2 stage of nodal involvement. 
All the cases showed lymph node involvement. 
 Margins were free in all the cases. 
 40% of the tumors were in Stage IIB and IIIA each. 
 60% of the tumors showed intermediate ER expression. 
 40% of the tumors showed weak and intermediate PR positivity each. 
 60% expressed HER2 neu positivity. (3+) 
 40% of the tumors had negative and 2+ expression of CK5/6 each. 
 All the cases had high proliferation index with Ki67. 
 On follow up, all the cases were alive and healthy. 
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 By McNemar’s test, the comparison of Luminal B type with the 
histopathological classification showed an inter rater agreement 
Kappa value of – 0.033 which indicates disagreement. 
HER2 TYPE 
 Most common age group is 40 - 49 years (38%). 
 Most common on the left side (82%). 
 The tumor was commonly located in the UOQ (63%). 
 The tumor size commonly ranged between 2cm and 5 cm (63%). 
 Most of the tumors in HER2 group were infiltrating ductal carcinoma 
NST (75%). 
 Among the variants, metaplastic carcinoma (one case) and lobular 
carcinoma (one case) belonged to HER2 group. 
  Among the IDC NST tumors, Grade III was the most common grade 
(50%). 
 The most common associated lesion was fibrocystic disease (63%). 
 88% of the tumors showed lymphovascular invasion. 
 38% of the cases had necrosis. 
 None of them showed skin involvement. 
 50% of the tumors belonged to N3 stage of nodal involvement. All 
the cases had lymph node involvement. 
 38% of the cases had involvement of margins. 
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 63% of the tumors were in Stage IIIA. 
 All the cases were negative for ER and PR expression. 
 88% expressed 3+ HER2 neu positivity.  
 63% of the tumors were negative for CK5/6. 
 75% of the cases had high proliferation index with Ki -67. 
 On follow up, 63% of the cases were alive and healthy. One case had 
recurrence and one death was reported. 
 By McNemar’s test, the comparison of HER2 type with the 
histopathological classification showed an inter rater agreement 
Kappa value of – 0.2 which indicates disagreement. 
 
HYBRID TYPE (Luminal + HER2) 
 Both 40 -49 and 50-59 years had equal distribution of cases (40%). 
 Most common on the right side (60%). 
 The tumor was commonly located in the UOQ (80%). 
 The tumor size commonly ranged between 2cm and 5 cm (80%). 
 The histological special variants constituted the most common type. 
Among which two cases were apocrine carcinoma and one was 
medullary carcinoma.  
 Among the IDC NST tumors, most common grade was grade II 
(40%). 
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 The most common associated lesion was fibrocystic disease (80%). 
 60% of the tumors showed lymphovascular invasion. 
 80% of the tumors showed lymphocytic infiltration. 
 20% of the cases had necrosis. 
 One case had skin involvement. 
 60% of the tumors exhibited N2 stage of nodal involvement. All the 
cases showed lymph node involvement. 
 Margins were involved in 20% of the cases. 
 All the cases belonged to Stage III. 
 All the cases showed intermediate ER expression. 
 40% of the tumors showed intermediate PR positivity. 
 All the cases showed 3+ HER2 neu positivity.  
 40% of the tumors had negative and 2+ expression of CK5/6 each. 
 80% of the cases had high proliferation index with Ki67. 
 On follow up, 60% of the cases were alive and healthy. One case of 
recurrence and one death was reported. 
 By McNemar’s test, the comparison of Hybrid type with the 
histopathological classification showed an inter rateragreement Kappa 
value of – 0.033 which indicates disagreement. 
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BASAL TYPE 
 Most common age group is 40 - 49 years (29%). 
 Most common on the left side (57%). 
 The tumor was commonly located in the UOQ (64%). 
 The tumor size commonly ranged between 2cm and 5 cm (72%). 
 Most of the tumors in basal type were infiltrating ductal carcinoma 
NST (57%). 
 Among the variants, two cases of apocrine carcinoma, three 
medullary carcinomas and one case of mucinous carcinoma belonged 
to Basal group. 
  Among the IDC NST tumors, Grade III was the most common grade 
(29%). 
 The most common associated lesion was fibrocystic disease (79%). 
 79% of the tumors showed lymphovascular invasion and lymphocytic 
infiltration. 
 21% of the cases had necrosis. 
 One case had skin involvement. 
 56% of the tumors belonged to N3 stage of nodal involvement. All 
the cases had lymph node involvement. 
 36% of the cases had involvement of margins. 
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 57% of the tumors were in Stage IIB. The only case in Stage IV 
disease belonged to this group. 
 93% of the tumors were negative for ER and PR expression. 
 86% were negative for HER2 neu.  
 57% of the tumors had 4+ expression of CK5/6. 
 86% of the cases had high proliferation index with Ki -67. 
 On follow up, 65% of the cases were alive and healthy. Four cases 
had recurrence and one death was reported. 
 By McNemar’s test, the comparison of Basal type with the 
histopathological classification showed an inter rater agreement 
Kappa value of – 0.133 which indicates disagreement. 
 
UNCLASSIFIED TYPE 
 Both 40 -49 and 50-59 years had equal distribution of cases (33%). 
 Both right and left sides had equal proportion of cases. 
 The tumor was commonly located in the UOQ (50%). 
 The tumor size commonly ranged between 2cm and 5 cm (50%). 
 Most of the tumors in unclassified group were infiltrating ductal 
carcinoma NST (83%). 
 Among the variants, metaplastic carcinoma (one case) belonged to 
unclassified group. 
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  Among the IDC NST tumors, Grade I was the most common grade 
(68%). 
 The most common associated lesion was fibrocystic disease (68%). 
 67% of the cases showed lymphocytic infiltration. 
 17% of the cases had necrosis. 
 33% of the cases had skin involvement. 
 67% of the tumors belonged to N2 stage of nodal involvement. Two 
cases did not have lymph node involvement. 
 33% of the cases had involvement of margins. 
 50% of the tumors were in Stage IIIA. 
 All the cases were negative for ER, PR and HER2 neu expression. 
 67% of the tumors were negative for CK5/6. 
 On follow up, 67% of the cases were alive and healthy. Two cases 
had recurrence. 
 By McNemar’s test, the comparison of HER2 type with the 
histopathological classification showed an inter rater agreement 
Kappa value of – 0.100 which indicates disagreement. 
 
COMPARISON AMONG MOLECULAR CLASSIFICATION 
 Luminal A and Luminal B showedhigherincidence of breast 
cancer in 50-59 age group with 40% incidence.HER 2(23%) and 
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basal types (20%) had ahigherincidence at an earlier age group of 
40-49 years. 
 Left side (58%) tumors were more common in all subtypes except 
hybrid type. 
 Upper outer quadrant (60%) was the most common site in all 
types. 
 Most of the tumors were between 2cm and 5cm (68%). Luminal 
B, HER2 and Unclassified types had a relatively increased 
incidence of tumors with more than 5cm size.  
 72% of luminal A tumors belongs to histological variants of 
special types rather than infiltrating ductal carcinoma NST. 
Whereas 40%, 25%, 42% and 16% of luminal B, HER 2, basal and 
unclassified types respectively belongs to variants. 
 The most common grade for HER2 was Grade III (50%). The 
association of histological grade with the molecular classification 
was statistically significant with the p value of 0.01. 
 The most common associated lesion was fibrocystic disease (73%) 
in all subtypes. DCIS was commonly associated with Basal (21%) 
and Unclassified types (33%). 
 66.7% of the tumors had lymphovascular invasion. Among which 
HER2 group had the highest incidence (88%). 
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 73% of the tumors had lymphocytic infiltration. Among which 
Luminal A had the highest incidence (83%). 
 Only 17% of the tumors had necrosis. Luminal B type (40%) 
tumors had the highest incidence. 
 8% of the tumors had skin involvement. Unclassified type (33%) 
tumors had the highest incidence. 
 Most of the tumors had N2 stage of nodal involvement. Basal type 
(56%) had the highest incidence of N3 stage. 
 23% of the tumors showed involvement of the margins. HER2 
type (38%) had the highest incidence. 
 Most of the tumors belonged to Stage II (62%). One case of Stage 
IV was Basal type.  
 ER, PR, HER2 neu, CK5/6 expression and proliferation index with 
Ki67 had a statistically significant association with the molecular 
classification. 
 High proliferation index (>14%) with Ki67 was noted in Luminal 
B, Basal and Hybrid types. 
 78% of the total 60 cases were alive and healthy. Unclassified type 
(33%) had the highest incidence of recurrence. One death was 
reported in HER2, Hybrid and Basal types. 
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INTER RATER AGREEMENT KAPPA 
 On evaluating the inter rater agreement between the histopathological 
and molecular classification which is quantified by the kappa statistic by 
using Mc Nemar’s test, it was found that all the subtypes showed 
negative kappa value. 
 This indicates that the agreement is worse than chance and hence the 
importance of molecular classification is substantiated for the targeted 
therapy. 
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CONCLUSION 
Breast carcinoma is one of the most commonly diagnosed cancers in 
females worldwide comprising 16% of all female cancer cases. Study of 
tumor molecular characteristics has enhanced our understanding of both the 
tumor behaviour and the response to therapy. In this study of 60 cases which 
included invasive ductal carcinoma NST and its variants, an attempt has 
been made to evaluate the hormonal status and proliferation index by 
immunohistochemistry. 
                        Luminal A and Luminal B showedhigherincidence of breast 
cancer in 50-59 age group.HER 2 and Basal types had ahigherincidence at 
an earlier age group of 40-49 years. Most of the tumors were left sided and 
situated in upper outer quadrant. Luminal B, HER2 and Unclassified types 
had a relatively increased incidence of tumors with more than 5cm size. 
72% of luminal A tumors belongs to histological variants of special types 
rather than infiltrating ductal carcinoma NST. Whereas 40%, 25%, 42% and 
16% of luminal B, HER 2, basal and unclassified types respectively belongs 
to variants. The association of histological grade with the molecular 
classification was statistically significant with the p value of 0.01.The most 
common associated lesion was fibrocystic disease in all the subtypes. DCIS 
was commonly associated with Basal and Unclassified types. Unclassified 
typeof tumors had the highest incidence of skin involvement.Most of the 
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tumors had N2 stage of nodal involvement. Basal type (56%) had the 
highest incidence of N3 stage.Most of the tumors belonged to Stage II. One 
case of Stage IV was Basal type. ER, PR, HER2 neu, CK5/6 expression and 
proliferation index with Ki67 had a statistically significant association with 
the molecular classification.High proliferation index (>14%) with Ki67 was 
noted in Luminal B, Basal and Hybrid types.78% of the total 60 cases were 
alive and healthy. Unclassified type had the highest incidence of recurrence. 
One death was reported in HER2, Hybrid and Basal types. 
 Not all triple negative tumors are basal types, only those tumors 
which express basal markers are categorised as basal type tumors and the 
rest which do not express are unclassified which has got a better 
prognosis.Ki67 plays an important role in categorising luminal tumors. 
On evaluating the inter rater agreement between the histopathological 
and molecular classification which is quantified by the kappa statistic by 
using Mc Nemar’s test, it was found that all the subtypes showed negative 
kappa value. This indicates that the agreement is worse than chance and 
hence the importance of molecular classification is substantiated for the 
targeted therapy. 
                   To conclude, breast cancers are heterogenous and having 
diverse clinical outcomes, these researches on molecular subgroups would 
pave way towards the “personalisation” of treatment for breast cancers with 
the more feasible and economic tool of immunohistochemistry. 
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ANNEXURE – I 
PROFORMA 
 
Case number  :      Name : 
HPE numbe   :     Age  : 
IP number   :     Sex  : 
Clinical diagnosis  :  
Menstrual status  : 
Risk factors if any  : 
Side of breast  : Right/Left 
Specimen    : Simple Mastectomy / Modified radical mastectomy /  
  Radical Mastectomy / Toilet mastectomy / Others 
 
GROSS 
Specimen size   : 
Nipple areola and Skin  : 
Tumor size    :     Tumor margin : 
Appearance    : 
Resected margins   : Superior :       Inferior :     
Medial :         Lateral :          
Posterior : 
Associated findings    : 
Total number of nodes dissected : 
Largest node size    : 
 
MICROSCOPY 
Histological subtype   : 
Histological score :   Nuclear score:    Mitotic score: 
Modified Scarf Bloom Richardson Grade:  I  /  II  /  III 
Skin              :     Free / Involved 
Nipple & Areola            :    Free / Involved 
Margins :   Superior : Free / Involved      Inferior : Free / Involved 
Medial : Free / Involved         Lateral : Free / Involved 
Posterior : Free / Involved 
Lymphatic invasion   : Present / Absent 
Vascular invasion    : Present / Absent 
Lymphocytic infiltration   : P resent / Absent 
Necrosis     : P resent / Absent 
Associated breast lesions   : 
Total number of nodes dissected : 
Number of nodes involved   : 
 
 
ANNEXURE II 
WHO HISTOLOGICAL CLASSIFICATION OF EPITHELIAL BREAST 
TUMORS 
INVASIVE BREAST CANCERS                                            NON INVASIVE BREAST CANCERS 
Invasive ductal carcinoma not otherwise specified          Ductal carcinoma in situ 
Mixed type carcinoma             Lobular carcinoma in situ 
Pleomorphic carcinoma             Atypical papilloma 
Carcinoma with osteoclastic type of giant cells         BENIGN EPITHELIAL TUMORS 
Carcinoma with choriocarcinomatous features         Tubular adenoma 
Carcinoma with melanotic features            Lactating adenoma 
Invasive lobular carcinoma              Apocrine adenoma 
Tubular carcinoma               Pleomorphic adenoma 
Invasive cribriform carcinoma             Ductal adenoma 
Medullary carcinoma               Papilloma 
Mucinous carcinoma               FIBROEPITHELIAL TUMORS 
Cystadenocarcinoma               Fibroadenoma 
Signet ring carcinoma              Phyllodes tumor 
Neuroendocrine tumors      Benign 
Solid neuroendocrine carcinoma     Borderline 
Atypical carcinoid tumor      Malignant 
Small cell/oat cell carcinoma              Periductal stromal sarcoma 
Large cell neuroendocrine carcinoma           Mammaryhamartoma 
Invasive papillary carcinoma     
Invasive micropapillary carcinoma  
Metaplastic carcinoma  
Apocrine carcinoma 
Pure epithelial metaplastic carcinoma 
Squamous cell carcinoma            METASTATIC TUMORS 
Adenocarcinoma with spindle cell metaplasia      
Adenosquamous carcinoma                                            
 Mucoepidermoid carcinoma                                             
Mixed epithelial/mesenchymal metaplastic carcinoma   
Lipid rich carcinoma  
Secretory carcinoma  
Oncocytic carcinoma 
Adenoid cystic carcinoma  
Acinic cell carcinoma                                                   
Glycogen rich carcinoma 
Sebaceous carcinoma 
Inflammatory carcinoma 
Intraductal papillary carcinoma 
Intracystic papillary carcinoma 
Microinvasive carcinoma 
INTRADUCTAL PROLIFERATIVE      
LESIONS 
Atypical ductal hyperplasia 
Flat epithelial atypia 
Usual epithelial hyperplasia 
 
 ANNEXURE III 
NOTTINGHAM MODIFICATION OF SCARF BLOOM 
RICHARDSON GRADING SYSTEM 
 
TUBULE FORMATION      SCORE 
Tubule formation in >75% of the tumor         1 
Tubule formation in 10 to 75% of the tumor        2 
Tubule formation in <10 % of the tumor         3 
 
NUCLEAR PLEOMORPHISM     SCORE 
Minimal variation in size and shape of nuclei       1 
Moderate variation in size and shape of nuclei       2 
Marked variation in size and shape of the nuclei       3 
 
MITOTIC RATE        SCORE 
<10 Mitosis per 10 high power field        1 
10 to 20 mitosis per 10 high power field       2 
>20 mitosis per 10 high power field         3 
 
GRADE         SCORE 
Grade 1:         3, 4, 5 
Grade 2:          6, 7  
Grade 3:         8, 9 
 
 
 ANNEXURE IV 
 
IMMUNOHISTOCHEMISTRY PROCEDURE 
 
1.  4μ thick sections were cut from formalin fixed paraffin embedded tissue samples 
and transferred to gelatin-chrome alum coated slides. 
2.  The slides were incubated at 58ºC for overnight. 
3.  The sections were deparaffinized in xylene for 15 minutes x 2 changes. 
4.  The sections were dehydrated with absolute alcohol for 5 minutes x 2 changes. 
5.  The sections were washed in tap water for 10 minutes. 
6.  The slides were then immersed in distilled water for 5 minutes. 
7. Heat induced antigen retrieval was done with microwave oven in appropriate 
temperature with appropriate buffer for 20 to 25 minutes. 
8. The slides were then cooled to room temperature and washed in running tap water 
for 5 minutes. 
9. The slides were then rinsed in distilled water for 5 minutes. 
10. Wash with appropriate wash buffer (phosphate buffer) for 5 minutes x 2 changes. 
11. Apply peroxidase block over the sections for 10 minutes. 
12. Wash the slides in phosphate buffer for 5 minutes x 2 changes. 
13. Cover the sections with power block for 15 minutes. 
14. The sections were drained (without washing) and appropriate primary antibody 
was applied over the sections and incubated for 45 minutes. 
15. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
16. The slides were covered with Super Enhancer for 30 minutes. 
17. The slides were washed in phosphate buffer for 5 minutes x 2 changes. 
18. The slides were covered with SS Label for 30 minutes. 
19. Wash in phosphate buffer for 5 minutes x 2 changes. 
20. DAB substrate was prepared by diluting 1 drop of DAB chromogen to 1ml of 
DAB buffer. 
21. DAB substrate solution was applied on the sections for 8 minutes. 
22. Wash with phosphate buffer solution for 5 minutes x 2 changes. 
23. The slides are washed well in running tap water for 5 minutes. 
24. The sections were counterstained with Hematoxylin stain for 2 seconds (1 dip). 
25. The slides are washed in running tap water for 3 minutes. 
26. The slides are air dried, cleared with xylene and mounted with DPX. 
 
ANNEXURE V 
ER, PR scoring 
 
Intensity is assigned 
0 = none, 
1 =weak,  
2 = intermediate, 
3 = strong, 
 
 
The scores are added together to obtain a total score that can range from 0 to 8. 
Tumors scoring 2 or less – ER negative and have a negligible chance of response. 
 
STAINING PATTERN AND HER2 NEU SCORING 
STAINING PATTERN SCORE HER 2/neu 
ASSESSMENT 
No staining or membrane staining 
observed in <10% of tumor cells 
0 Negative 
A faint/barely perceptible membrane 
staining observed in >10% of the 
tumor cells 
1+ Negative 
A weak to moderate complete 
membrane staining observed in 
>10% of the tumor cells. 
2+ Positive 
A strong complete membrane 
staining observed in >30% of the 
tumor cells.  
3+ Positive 
 
Proportion as 
0 = none,  
1 = <1/100,  
2 = 1/100 to 1/10, (1-10cells/100 cells) 
3 = 1/10 to 1/3, (11-33.3 cells /100 cells) 
4 = 1/3 to 2/3, (34-66.7 cells /100 cells)  
5 = >2/3. (>67 cells/100 cells) 
 CK 5/6 SCORING 
Score 1: 25% of the tumour tissue shows positivity. 
Score 2: 26-50% of cells were positive. 
Score 3: 51-75% showed positivity. 
Score 4: 76-100% was positive. 
 
S.NO HPE NO Age SexSide P/D TL Size HT G AL LVI LYI Nec SK LNI/LND M ST TG F UP ER PR H2N CK Ki67 MC T OP
1 2174/11 50 F R MRM UOQ 4 MET FCD P A A A I/9 FREE IIb S+6+RT A&H 3+3 3+2 2+ 1+ HI LB S+3+PB+RT
2 3144/11 52 F R MRM CQ 3 PAP FCD A P A A O/9 FREE IIA S+6 A&H 3+2 4+3 0 0 LO LA S+HT+3
3 5098/11 45 F L MRM CQ 6 MET FCD P A A A II/8 FREE IIIA 3+S+RT D 1+1 1+1 0 3+ HI BA 3+S+PB+RT
4 5223/11 54 F L MRM LOQ 3 LOB DCIS P A A A III/9 FREE IIB S+3+RT A&H 4+3 3+3 0 0 LO LA S+HT+RT
5 5451/11 54 F R MRM CQ 7 MET DCIS P P A A V/5 POST IIIA 3+S+3+RT A&H 3+2 3+2 1+ 1+ LO LA S+HT+RT
6 6973/11 43 F L MRM UOQ 3 APO FCD P P A A VIII/11 FREE IIIA S+3+RT A&H 3+3 3+2 3+ 1+ LO L+H S+PB+HC+RT
7 7448/11 54 F L MRM UOQ 4 PAP FCD A P A A II/7 FREE IIB S+3+RT A&H 3+3 2+3 0 0 LO LA S+HT
8 7692/11 58 F L MRM CQ 10 MET FCD A P P P II/12 FREE IIIA 3+S+3+RT REC 0+0 0+0 0 2+ HI UC S+3+PB+RT
9 7709/11 45 F L MRM UOQ 5 MED FCD A P A A O/12 FREE IIA S+3 A&H 3+3 3+2 2+ 1+ HI LB S+3+PB+RT
10 7764/11 70 F R MRM CQ 4 MUC FCD P P A A I/9 FREE IIB S+3+RT A&H 0+0 0+0 0 3+ LO BA S+HT+PB+RT
11 7891/11 53 F R MRM UOQ 5 MET FCD A P A A I/9 FREE IIB S+3 A&H 4+2 1+1 0 0 LO LA S+HT
12 1353/12 44 F R MRM CQ 3 APO FCD A P A A II/9 FREE IIB S+3 A&H 1+1 1+1 0 3+ HI BA S+PB+RT
13 1523/12 41 F L MRM UIQ 3 PAP FCD A P A A O/9 FREE IIA S+3 A&H 2+3 4+3 0 0 LO LA S+HT
14 1696/12 56 F R MRM UOQ 3 MED FCD A P A A II/10 FREE IIB 3+S REC 0+0 0+0 0 4+ HI BA S+3+PB+RT
15 3467/12 61 F L MRM LOQ 2 LOB FCD P P A A I/7 FREE IIA S+3+RT A&H 3+3 4+2 0 0 LO LA S+HT+RT
16 4653/12 65 F R MRM UOQ 6 MUC FCD A P A A O/9 FREE IIB 3+S+3 A&H 3+3 3+3 0 1+ LO LA S+HT
17 5159/12 45 F R MRM CQ 9 MUC FCD A P A P III/9 SKIN IIIB 3+S+RT A&H 3+3 3+3 0 1+ LO LA 3+S+HT
18 8213/12 58 F L MRM CQ 5 MED FCD P P A A III/21 FREE IIB 3+S+3+RT A&H 4+2 5+3 0 1+ LO LA S+HT+RT
19 8236/12 50 F R MRM UOQ 6 MED SA P P A A XII/12 FREE IIIC 3+S+3+RT REC 3+3 4+3 3+ 0 HI L+H S+HC+PB+RT
20 9235/12 48 F L MRM UOQ 4 APO FCD P P A A II/7 FREE IIB S+3+RT A&H 0+0 0+0 0 3+ HI BA S+3+PB+RT
21 9737/12 65 F L MRM UOQ 5 MUC FCD P P A A O/7 FREE IIA S+3 A&H 4+2 4+3 0 1+ LO LA S+HT+RT
22 1069/13 62 F R MRM UOQ 5 IDC NST I FCD A P A A II/13 POST IIB S+6+RT A&H 1+1 1+1 0 2+ HI UC S+PB+RT
23 1868/13 52 F R MRM UOQ 4 IDC NSTIII DCIS P P P A O/11 FREE IIA S+6+RT A&H 1+1 1+1 1+ 3+ HI BA S+3+PB+RT
24 1899/13 55 F L MRM CQ 3 IDC NSTIII FCD P A A A IV/7 FREE IIIA S+6+RT REC 4+3 3+3 3+ 1+ HI L+H S+3+PB+RT
25 2351/13 35 F L MRM CQ 5 IDC NSTIII SA p A A A IV/8 POST IIIA S+6+RT A&H 0+0 0+0 3+ 1+ LO H S+HC+RT
26 2778/13 45 F R MRM CQ 5 IDC NST II FCD A P P P O/13 FREE IIIB S+6 A&H 0+0 1+1 0 4+ HI BA S+HC+3+PB+RT
27 2916/13 55 F R MRM LOQ 5 LOB DCIS P A A A II/8 FREE IIB S+3+RT A&H 3+3 2+3 0 1+ LO LA S+HT+RT
28 3428/13 40 F L MRM CQ 8 IDC NST I FA A P A A I/7 FREE IIIA S+3+RT A&H 2+1 1+1 3+ 1+ HI H S+HT+HC+RT
29 3446/13 50 F L MRM UOQ 3 IDC NST II FCD P P A A VII/10 LAT IIIA S+6+RT D 5+3 3+3 3+ 0 HI L+H S+HC+PB+RT
30 3765/13 65 F R MRM UOQ 6 IDC NST I FCD A P A A VII/13 FREE IIIA S+6+RT REC 3+1 2+1 2+ 2+ HI LB S+HC+RT
31 4161/13 72 F L MRM UOQ 3 IDC NST II SA P P A A I/7 FREE IIB 3+S+3 A&H 5+3 2+3 0 1+ LO LA S+HT+RT
32 5379/13 55 F L MRM UOQ 3 IDC NSTIII FCD P P A A O/12 FREE IIA S+6+RT A&H 0+0 0+0 3+ 1+ HI H S+HC+RT
33 5429/13 50 F L MRM CQ 7 IDC NST I FCD P P A A O/11 POST IIB 3+S+3+RT A&H 1+1 0+0 2+ 3+ HI BA S+3+PB+RT
34 5601/13 45 F L MRM 4 IDC NSTIII FCD P P A A VII/12 FREE IIIA S+6+RT REC 0+0 0+0 3+ 0 HI H S+HC+RT
35 5882/13 65 F L MRM UOQ 6 LOB DCIS P P P A VII/15 POST IIIA S+6+RT A&H 0+0 0+0 3+ 0 HI H S+HC+RT
36 6377/13 48 F L MRM UOQ 7 IDC NST I DCIS P P A A O/13 FREE IIB S+3 A 0+0 0+0 0 4+ HI BA S+PB+RT
37 6513/13 59 F L MRM LOQ 2 IDC NST I DCIS P P A P O/13 FREE I S+3 REC 0+0 0+0 0 1+ HI UC S+PB+RT
38 6639/13 37 F R MRM UOQ 5 IDC NST I FCD P P A A III/9 POST IIB S+6+RT A&H 3+2 3+2 0 0 LO LA S+HT+RT
39 6957/13 50 F L MRM LOQ 3 IDC NSTII SA P P A A O/9 FREE IIB S+3 A&H 0+0 0+0 3+ 1+ LO H S+HC
40 6959/13 54 F L MRM UOQ 3 IDC NST II FCD P P A A O/14 FREE IIA S+3 A&H 0+0 0+0 0 3+ HI BA S+PB+RT
41 7004/13 46 F L MRM UOQ 4 PAP FCD P A A A II/6 FREE IIB S+3+RT A&H 4+3 3+3 0 0 LO LA S+HT+RT
42 7093/13 75 F R MRM UOQ 4 MUC DCIS P P A A III/11POST AND LAT IIB S+3+RT+3 A&H 3+3 3+3 0 1+ LO LA S+HT+RT
43 7153/13 42 F R MRM UOQ 6 IDC NST I DCIS P P A A II/10 FREE IIIA 3+S+T+RT A&H 1+1 0+0 0 1+ HI UC S+3+RT
44 7160/13 35 F L MRM UOQ 6 IDC NST III FCD P P P A V/11 FREE IIIA S+3+RT A&H 3+3 3+2 2+ 1+ HI LB S+3+PB+RT
45 7164/13 60 F R MRM UOQ 3 APO FCD A P A A IV/9 FREE IIIA S+6+RT A&H 4+3 4+3 3+ 0 HI L+H S+HC+PB+RT
46 7173/13 60 F L MRM UIQ 8 IDC NST II FCD P P A A O/9 FREE IIB 3+S+3 A&H 5+3 0+0 0 1+ HI LA S+HT+3
47 7285/13 51 F R MRM UOQ 3 IDC NST II FCD A P A A O/7 FREE IIA S+3 A&H 0+0 0+0 0 4+ HI BA S+PB
48 7433/13 26 F R MRM CQ 5 MED FCD P P A A V/11 POST IIIA S+3+RT D 0+0 0+0 0 4+ HI BA S+PB+RT
49 7478/13 67 F L MRM UOQ 4 APO FCD P P A A II/6 FREE IIB S+3+RT A&H 3+2 2+2 2+ 1+ HI LB S+HT+RT
50 7552/13 63 F L MRM UOQ 4 LOB FCD P P A A II/7 FREE IIB S+3+RT A&H 3+3 4+2 0 1+ LO LA S+HT+RT
51 7608/13 42 F R MRM UOQ 2 IDC NST I FCD A P A A O/7 FREE I S+3 A&H 3+3 4+2 0 0 LO LA S+HT+RT
52 7750/13 42 F L MRM UOQ 3 IDC NST II FCD P P A A III/8 FREE IIB S+3 A&H 0+0 0+0 0 4+ LO BA S+PB+RT
53 7986/13 57 F L MRM UIQ 3 PAP FCD A P A A O/8 FREE IIA S+6 A&H 4+3 2+3 0 0 LO LA S+HT
54 8034/13 32 F R MRM LOQ 5 IDC NST I FCD A P A A O/7 FREE IIA S+3 A&H 0+0 1+1 1+ 0 LO UC S+3+RT
55 8407/13 59 F R MRM UOQ 4 IDC NST II DCIS A P A A IV/9 FREE IIIA S+3+RT A&H 4+2 2+2 0 0 HI LA S+HT+RT
56 8469/13 48 F L MRM UOQ 4 IDC NST III FCD P P P A III/8 POST IIB 3+S+3+RT REC 1+1 1+1 3+ 0 HI H S+HC+RT
57 8552/13 67 F L MRM UOQ 2 IDC NST III DCIS P P A A III/8 MED IIA S+3+RT A&H 0+0 1+1 0 3+ HI BA S+PB+RT
58 8593/13 67 F R MRM UOQ 7 IDC NST III FCD P P P P II/9 SKIN IIIB 3+S+3+RT REC 0+0 0+0 1+ 4+ HI BA S+PB+RT
59 8781/13 62 F R MRM UOQ 3 IDC NST I FCD P P P A III/8 POST IIB S+3+RT A&H 1+1 0+0 0 4+ HI BA S+PB+RT
60 8828/13 42 F L MRM UOQ 4 IDC NST III FCD P P A A IV/9 POST IIIA S+6+RT REC 0+0 0+0 0 0 HI UC S+3+RT
KEY TO MASTER CHART 
 
M   : Male 
F   : Female 
R   : Right 
L   : Left 
P/D   : Procedure Done 
MRM   : Modified radical mastectomy 
TL   : Tumor location 
UOQ   : Upper Outer Quadrant 
UIQ   : Upper inner quadrant 
CQ   : Central Quadrant 
HT   : Histological type 
IDC NST  : Infiltrating ductal carcinoma – No special type 
PAP   : Invasive papillary carcinoma 
MET   : Metaplastic carcinoma 
MED   : Medullary carcinoma 
MUC   : Mucinous carcinoma 
APO   : Apocrine carcinoma 
LOB   : Lobular carcinoma 
G   : Grade 
AL   : Associated lesions 
DCIS   : Ductal carcinoma in situ 
FCD   : Fibrocystic disease 
SA   : Sclerosing adenosis 
LVI   : Lymphovascular invasion  
LYI   : Lymphocytic infiltration 
Nec   : Necrosis 
SK   : Skin involvement 
LNI/LND  : lymph nodes involved/ lymphnodes dissected 
M   : Margins 
P   : Present/positive 
A   : Absent 
N   : Negative 
POST   : Posterior margin 
LAT   : Lateral margin 
MED   : Medial margin 
SUP   : Superior margin 
INF   : Inferior margin 
ST   : Stage 
ER   : Estrogen receptor 
PR   : Progesterone receptor 
H2N   : Her 2 neu 
CK   : Cytokeratin 5/6 
Ki67   : Ki67 labelling index 
MC   : Molecular classification 
LA   : Luminal A 
LB   : Luminal B 
H   : HER2  
L+H   : Luminal + HER2 hybrid 
BA   : Basal 
UC   : Unclassified 
TG   : Treatment given 
T OP   : Treatment option 
S   : Surgery 
RT   : Radiotherapy 
HT   : Hormonal therapy 
3   : 3 drug regimen chemotherapy 
6   : 6 drug regimen chemotherapy 
HC   : Herceptin 
PB   : Platinum based chemotherapy 
F UP   : Follow up 
A&H   : Alive and healthy 
A&R   : Alive with recurrence 
D   : Dead 
 
 


